
==== Front
Cell Commun Signal
Cell Commun Signal
Cell Communication and Signaling : CCS
1478-811X
BioMed Central London

1802
10.1186/s12964-024-01802-8
Review
Role of G protein coupled receptors in acute kidney injury
Lv Liangjing
Liu Yong
Xiong Jiachuan
Wang Shaobo
Li Yan
Zhang Bo
Huang Yinghui
Zhao Jinghong zhaojh@tmmu.edu.cn

grid.410570.7 0000 0004 1760 6682 Department of Nephrology, the Key Laboratory for the Prevention and Treatment of Chronic Kidney Disease of Chongqing, Chongqing Clinical Research Center of Kidney and Urology Diseases, Xinqiao Hospital, Army Medical University, Third Military Medical University), Chongqing, 400037 China
2 9 2024
2 9 2024
2024
22 42311 6 2024
20 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Acute kidney injury (AKI) is a clinical condition characterized by a rapid decline in kidney function, which is associated with local inflammation and programmed cell death in the kidney. The G protein-coupled receptors (GPCRs) represent the largest family of signaling transduction proteins in the body, and approximately 40% of drugs on the market target GPCRs. The expressions of various GPCRs, prostaglandin receptors and purinergic receptors, to name a few, are significantly altered in AKI models. And the role of GPCRs in AKI is catching the eyes of researchers due to their distinctive biological functions, such as regulation of hemodynamics, metabolic reprogramming, and inflammation. Therefore, in this review, we aim to discuss the role of GPCRs in the pathogenesis of AKI and summarize the relevant clinical trials involving GPCRs to assess the potential of GPCRs and their ligands as therapeutic targets in AKI and the transition to AKI-CKD.

Supplementary Information

The online version contains supplementary material available at 10.1186/s12964-024-01802-8.

Keywords

G protein-coupled receptors (GPCRs)
Acute kidney injury
GPCR ligands
Chongqing Graduate Innovation ProgramCYB23291 National Key R&D Program of China2022YFC2502500/2022YFC2502501 Key Program of the Natural Science Foundation of ChinaNo.82030023 the Natural Science Foundation of ChinaNos.82322012, U22A20279, 81800616 Frontier specific projects of Xinqiao HospitalNo. 2018YQYLY004 issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcIntroduction

Acute kidney injury (AKI) is a significant public health problem that is associated with high morbidity and mortality. Clinically, AKI is characterized by a sustained 7-day reduction in urine output and/or a significant increase in serum creatinine levels [1]. The prevalence of AKI is 10–15% in hospitalized patients and can be as high as 50% in intensive care unit patients, with 10–20% requiring renal replacement therapy [2]. The average pooled mortality rate for AKI is 23%, which can increase up to 49.4% in those requiring KRT [1]. AKI can be classified into pre-renal, renal and post-renal injury, depending on the site and etiology of the lesion. Pre-renal factors include volume depletion, hypotension and other ischemia-reperfusion injuries. Renal factors include nephrotoxic drugs and sepsis, and approximately 20% of AKI cases are related to nephrotoxic drug exposure. Post-renal AKI is mainly caused by urinary tract obstruction, which accounts for about 5% of AKI cases [3, 4]. Although the pathological mechanisms may differ among different causes of AKI, they all ultimately lead to the loss of renal function. The kidney has the ability to repair damage, and the degree of AKI injury can affect the outcome. Recent advances in technology, such as single-cell RNA sequencing and chromatin accessibility analysis, have provided new insights into the mechanisms of AKI injury, and emerging mechanisms, such as metabolic reprogramming and iron death, are being explored [1]. However, most of these studies are still at the preclinical stage, and clinical treatment of AKI mainly focuses on managing symptoms, as effective and feasible therapeutic measures are still lacking.

G protein-coupled receptors (GPCRs) are the most extensive family of cell membrane receptors associated with signal transduction, and they are widely distributed throughout the body. These receptors have various endogenous ligands such as odors, hormones, neurotransmitters, and chemokines, which have diverse forms such as photons, lipids, and peptides [5, 6]. Based on their amino acid sequences, GPCRs can be classified into different subfamilies, including Class A (retinoid), Class B (secretin and adhesion), Class C (glutamate), and Class F (coiled-coil). These subfamilies have some structural commonness, such as the presence of seven transmembrane structures, but they also have their unique structural characteristics, as shown in Fig. 1. The diverse structure of GPCRs determines the uniqueness and diversity of their functions. GPCR activation methods are diverse and include classical “GPCR-G protein” activation, biased activation, and dimerization activation (Fig. 2). Different receptor activation modes exert unique biological functions through various downstream pathways, including G protein-dependent and non-G protein-dependent pathways (Fig. 3).

Fig. 1 Structural characteristics and classification of GPCRs. The structures of various GPCR subfamilies are different. For class A, the extracellular N-terminus is short. Their native ligands directly bind to the transmembrane region or indirectly affect their conformation by binding to extracellular loop structures. Of note, chemokines and glycoprotein hormone receptors have long N-terminal domains. For class B1, the extracellular N-terminus is long, which binds to hormones such as vasoactive intestinal peptide (VIP), adrenocorticotropic hormone-releasing factor (CRF), and calcitonin gene-related peptide (CGRP), respectively. For class B2, the extracellular N-terminus is long, with multiple adhesion domains and a GPCR auto-proteolytic site(GPS site). aGPCR is unique in that the extracellular GPS site cleavage exposes the stachel fragment to bind to the transmembrane region and thus activates itself. For class C, there is a larger double-lobe N-terminus, also known as the “dreamcatcher” structure, which can form a dimeric structure with a unique activation pattern. Class F subfamily contains 10 frizzled receptors (FZD1-10) and 1 smoothened receptor (SMO). The extracellular domain contains approximately 120 amino acids (FZ domain, also known as cysteine-rich domain, CRD). FZD-GPCRs transmit signals via the Wnt pathway, while SMOs transmit signals via the Hedgehog pathway

Fig. 2 Activation mode of GPCRs. The activation of membrane receptor GPCR depends on the binding of its ligand. In classic “GPCR-g protein” activation mode, GPCR undergoes conformational changes after binding, and then interacts with intracellular G protein. And the activated G protein transducts and amplifies GPCR signals through the second messenger, producing a variety of cellular responses. In biased activation, ligands selectively activate the activation mode mediated by the β-arrestin pathway. As for dimerization activation, GPCRs do not always exist in monomeric form, and dimerization is also important for certain functions and activation of GPCR signaling pathways. Some GPCRs can be conjugated as either monomers or dimers, and both can activate different downstream signaling pathways. Of note, some GPCR dimerization can be understood as a switch of the conjugated G protein or arrestin molecule. Besides, some GPCRs can be activated within cells and trigger specific downstream effects, so-called “intracellular activation”. There are at least two explanations for the activation of intracellular GPCRs: First, GPCRs can continue to signal after internalization with their agonists. Second, GPCRs located on different organelle membranes, such as GPR78, can be activated intracellularly

Fig. 3 GPCRs downstream signalings. GPCRs downstream pathways of can be roughly divided into two categories: G protein-dependent signaling pathways and non-G protein-dependent (β-arrestin-dependent) signaling pathways. G protein-dependent signaling pathways require G protein involvement, in short, the human body has 16 Gα, 5 Gβ and 13 Gγ subunits that can combine to form a variety of heterotrimeric G proteins. Each Gα subunit is able to signal independently, while the Gβ subunit and Gγ subunit are obligate heterodimers as a single unit (Gβγ). The 16 Gα subunits can be divided into 4 major Gα families (Gs, Gi/o, Gq/11, and G12/13), which regulate the function of key effector factors(adenosine cyclase(AC), phospholipase C(PLC)) that affect the generation of secondary messengers (cAMP, Ca2+, etc.), which in turn triggers different signaling cascades. Many different GPCRs can be conjugated to the same Gα protein, and the same GPCR can also be conjugated to multiple Gα proteins. As for non-G protein-dependent signaling pathways, ligands-activated or self-activated GPCRs integrate and transduce extracellular signals by β-arrestin. Phosphorylation of GPCRs by GRK results in the recruitment of β-arrestin, a key molecule of signaling of GPCRs, which can mediate the desensitization of GPCRs, recruit enzymes for second messenger degradation and mediate the internalization of GPCRs, and can also mediate a variety of signal transduction including Src, EGFR, MAPK, PI3K/Akt signaling pathways

GPCRs are implicated in many diseases, including depression, Alzheimer’s disease, and cancer. Presently, approximately 40% of available drugs target GPCRs, and GPCRs are the focus of around 60% of ongoing clinical trials [7]. The emergence of cryo-electron microscopy and crystallography techniques has shed new light on the number of GPCR crystal structures, and advancements in cross-disciplinary technologies, such as nuclear magnetic resonance spectroscopy and artificial intelligence, have provided new insights into the structure and function of GPCRs. Consequently, GPCR-based drug research has entered a new stage. However, research on GPCRs related to AKI is relatively limited and dispersed when compared to studies on neurological and cancer-related GPCRs, which somewhat limits the structural advantages of GPCR in drug development for AKI. Therefore, this paper aims to review newly discovered GPCRs, such as metabolism-related receptors, cannabinoid receptors and orphan receptors, that have important roles in AKI pathogenesis, and briefly summarize the existing AKI-related GPCRs, such as Ang receptors, chemokines and complement receptors (Supplementary Table 1).

Role of GPCR in AKI

The kidney is a vital organ that maintains homeostasis by regulating blood pressure, electrolyte balance, and blood components. It performs excretory and endocrine functions and consists of functional units called nephron. These units are composed of glomeruli, capillaries, and tubules, which are comprised of different cell types. The number of nephron is established at birth and decreases with age, particularly after 25 years of age [1]. Although the mechanism of injury may vary, all forms of AKI can ultimately lead to loss of kidney function. Mild renal impairment can be repaired by the kidneys themselves, while severe AKI injury can result in atypical repair, leading to CKD or even ESRD [8].

Renal blood flow is abundant, accounting for 25% of cardiac output in the resting state, and 90% of renal blood flow is perfused to the cortex. The countercurrent arrangement of the microvasculature allows for urine concentration, but also makes renal tissue particularly sensitive to hypoxia, which affects tissue oxygenation [9]. In addition, the kidney has high energy demands due to its metabolic activity in reabsorbing electrolytes and nutrients from tubular fluid into the blood and secreting waste products from the blood into tubular fluid [10]. The high energy demand renders renal tissue more sensitive to hypoxia, particularly the proximal tubular cells, which are primarily supplied by fatty acid oxidation in the physiological state. In AKI, there is a disruption of the energy balance, enhancement of glycolysis and pentose phosphate pathways, and immunometabolic reprogramming of intrarenal cells [11]. These changes further link hemodynamic changes and cause a series of injuries.

Hemodynamics

The kidney plays a crucial role in regulating blood pressure and fluid homeostasis in the body. Inadequate renal perfusion due to factors such as volume depletion and hypotension can lead to a decrease in the glomerular filtration rate. This alteration can activate the renin-angiotensin system (RAS) when macula densa sense the changes in NA + concentration in the lumen of the distal convoluted tubule. Continuous activation of the RAS system can cause hemodynamic alterations that promote a series of injuries, including hypoxia, metabolic disorders, and inflammation.

Angiotensin II Receptors and Mas Receptors

Angiotensin is a crucial component of the RAS, which plays a significant role in regulating blood pressure and fluid homeostasis. The RAS system’s involvement in AKI has garnered considerable attention in research field [12–14]. The RAS system operates through two axes in the kidney, namely the classical axis, which comprises Angiotensin II (Ang II), Angiotensin-Converting Enzyme (ACE), and Angiotensin II Type 1 Receptor (AT1R), and the non-canonical axis, which consists of Angiotensin [1–7] (Ang 1–7), Angiotensin-Converting Enzyme 2 (ACE2), and MasR. These two axes function differently in AKI, with the former increasing blood pressure, promoting inflammation, and causing endothelial dysfunction [15], while the latter reduces blood pressure and exerts anti-inflammatory and anti-fibrotic effects. The angiotensin receptors AT1R, AT2R and MasR are class A GPCRs (Supplementary Table 1). Their expression in the kidney is shown in Table 1 (mouse) and Supplementary Table 2 (human). When renal ischemia-reperfusion injury occurs, the dynamic balance between the two axes is disrupted. The role of the classical axis in AKI has long been established and numerous clinical studies have shown the protective effect of its inhibition in AKI [16]. For example, RAS system inhibitors such as losartan can reduce the risk of secondary CKD in cardiac surgery-related AKI [17], reducing severe mortality in AKI patients at 1 year by approximately 52% [18].

Table 1 Expression of GPCRs related to renal hemodynamics in mouse

Gene_symbol	Glomeruli	PTS1	PTS2	PTS3	DTL1	DTL2	DTL3	ATL	MTAL	CTAL	DCT	CNT	CCD	OMCD	IMCD	
Agtr1a	396.0	51.6	22.8	7.9	3.4	3.8	1.2	1	0.6	2	0.8	0.2	0.4	0.8	0.3	
Agtr1b	0.4	0	0	0	0.4	0	0.1	0	0	0	0	0	0	0	0	
Agtr2	0.5	0	0	0	0.8	0.3	0.7	0.3	0	0.5	0	0	0	0	0	
Ptger1	4.6	0.4	0.5	0.5	3.7	3	4.6	15.5	2.1	2	1.2	29.5	86.4	494.5	336.3	
Ptger2	7.4	0.1	0	0	2	1.9	32.3	0.3	0.1	0	0	0	0	0.3	0	
Ptger3	2.1	7.3	0.2	0	4.5	1.3	1.5	36.4	729.4	511.5	18.3	64.5	26.9	1.3	0.2	
Ptger4	97.0	0.2	0.1	0.4	20.7	5.8	7.4	2.7	0.5	4.4	0.7	13.4	19.2	11	0.4	
The expression of GPCRs mentioned above is extracted from the database providing the mean gene expression values (transcripts per million, TPM) for micro-dissected mouse renal glomeruli (https://esbl.nhlbi.nih.gov/MRECA/G/) and tubule segments (https://esbl.nhlbi.nih.gov/MRECA/Nephron/). GlOM, glomerulus; PTS1, the initial segment of the proximal convoluted tubule; PTS2, the proximal straight tubule in cortical medullary rays; PTS3, the last segment of the proximal straight tubule in the outer stripe of outer medulla; DTL1, the short descending limb of the loop of Henle; DTL2, the long descending limb of the loop of Henle in the outer medulla; DTL3, the long descending limb of the loop of Henle in the inner medulla; ATL, the thin ascending limb of the loop of Henle; MTAL, medullary thick ascending limb of the loop of Henle; CTAL, cortical thick ascending limb of the loop of Henle; DCT, the distal convoluted tubule; CNT, the connecting tubule; CCD, cortical collecting duct; OMCD, outer medullary collecting duct; IMCD, inner medullary collecting duct

On the contrary, the protective role of the non-canonical axis against AKI has received attention in recent years. Based on data from preclinical studies, the expression of AT2R decreases during growth and development [19], and is only found in some organs after birth, but is overexpressed in pathological states [20]. Compared to AT1R, AT2R plays a protective role in the organism by counteracting the various effects of AT1R [21–23]. In ischemic reperfusion injury, AT2R agonist C21 protects renal tubular cells and alleviates injury through the GTPase/RhoA/Cdc42 pathway [24]. In LPS-induced injury, C21 down-regulates the expression of inflammatory factors such as IL-6 and TNF-α and alleviates kidney injury; while this effect is lost locally in the kidney after IL-10 neutralizing antibody treatment, suggesting that the protective effect of AT2R agonist C21 is mediated by IL-10 [25]. MasR is also a member of the descending axis and is presented in various tissues such as heart, kidney, lung, and liver [16], and its ligand Ang [1–7] is protective in the kidney. Accordingly, Ang [1–7] alleviates oxidative stress, inflammation, and apoptosis via MasR in renal injury induced by rhabdomyolysis in rat [26]. Nevertheless, the role of MasR in the kidney is controversial. Studies have shown MasR expression is increased in tubule after IRI in rat [27]; AVE0991 (MasR antagonist) ameliorates IRI-induced tubular injury such as tubular vacuolization and tubular necrosis; however, in MasR knockout mice, ischemia-reperfusion injury on kidney is no significantly different from that of WT mice [28]. In lipotoxic nephropathy, Mas receptor-mediated palmitic acid (PA)-induced renal autophagy and ER stress [29]. Nevertheless, in the UUO model, renal inflammation and apoptotic damage were exacerbated in Mas knockout mice compared to WT mice [30]. Further studies are needed to investigate the role of MasR in AKI and the possible biased signaling of MasR.

Prostaglandin receptors

Prostaglandins (PGs) are hormone-like metabolites of arachidonic acid (AA). PGE2, one of the most abundant prostaglandins in the kidney, is produced by all kinds of renal cells and can serve as a chemical signal regulator involved in various biological functions such as blood pressure regulation and fluid homeostasis [31]. Due to its short half-life, PGE2 is released extracellularly in an autocrine or paracrine manner and binds to specific receptor to exert various biological functions. There are four PGE2 receptors (EP1-4) and their expression in the kidney is shown in Table 1 (mouse) and Supplementary Table 2 (human). Physiologically, the regulation of hemodynamics of PGE2 through EPs is closely related to the water channel protein AQP2 [31, 32]. In AKI, EP4 receptors are of great importance due to high expression in immune cells such as macrophages in renal interstitials [33, 34]. There is growing evidence that PGE2/EP4 ameliorates renal I/R injury through various antioxidant, anti-apoptotic and anti-inflammation effects [35, 36]. In our previous study, we also found, in AKI mouse model, EP4 was significantly increased mainly in macrophages but not tubular cells. Activated EP4 inhibited macrophage polarization (decreased M1/M2 ratio) by inducing carnitine palmitoyltransferase 2 (CPT2)-mediated macrophage lipid autophagy to delay AKI progression to CKD [37]. Furthermore, we recently found in gentamicin-induced zebrafish kidney single-cell RNA sequencing data that renal interstitial cells(RICs) secrete PGE2, which promotes proliferation and regeneration of renal cells by activating EP4 on renal progenitor cells [38]. Notably, different EP4 agonists may exert different effects. For example, CAY10598 inhibits IRI-induced mitochondrial dysfunction and alleviates apoptosis [39], while EP4-selective agonist (ONO-AE1-329) increases neutrophil infiltration exacerbating IRI injury [40].

Intercellular stress

Renal tubular cells are the most abundant cell type in the kidney and are critical for substance transport and reabsorption of glomerular filtrate. Renal tubular cells, especially proximal tubular cells, have high mitochondrial content, high energy requirements, and metabolism-related signaling that is essential for the proper functioning of TECs, which also makes them susceptible to oxidative and metabolic stress [1]. Both ischemia-reperfusion injury and cytotoxicity caused by drugs such as cisplatin disrupt tubular cell mitochondrial function and metabolism, especially glycolysis and fatty acid oxidation processes. Long-term abnormalities in metabolic homeostasis lead to tubular cell death and subsequent development of CKD [1].

Purine metabolism and adenosine receptors.

ATP is a crucial energy source for intracellular reactions. However, its negative charge prevents it from crossing the cell membrane freely, resulting in a concentration of extracellular ATP (eATP) that is 1000 times lower than intracellular ATP (iATP) under normal physiological conditions [41]. In response to cellular stress or injury, iATP is released extracellularly via exocytosis or active transport, and exerts signaling functions by binding membrane-anchored ionotropic receptors P2XRs and metabotropic P2YRs [42, 43], which belong to class A GPCRs. Their expression in the mouse and human kidney is shown in Table 2 and Supplementary Table 2, respectively. eATP can be degraded to AMP/ADP by the ectonucleotidase CD39, and AMP/ADP can be further degraded to adenosine by the ectonucleotidase CD73 [42, 43]. In the kidney, CD39 exhibits greater enzymatic efficiency than CD73, resulting in a higher local production of AMP/ADP than adenosine [41]. Various types of renal injury lead to increased extracellular ATP concentrations, as well as deficient expression of proximal tubular CD73 and increased concentrations of eAMP/ADP, resulting in sustained activation of purinoceptors [41]. Our previous study [44] found that P2 × 7R expression was upregulated in renal tubular cells of mice with cisplatin-induced AKI. Blocking P2 × 7R ameliorated injury by decreasing inflammatory vesicle components, oxidative stress, and caspase-3 activity. Accordingly, P2 × 7R is a major factor in NLRP3 inflammatory vesicle activation in IRI in mouse [45] and sepsis-induced AKI in rat [46]. In addition, studies have shown that elevated extracellular UDP concentrations activate P2Y14 receptors, promoting chemokine expression and renal infiltration of neutrophils and monocytes in IRI mice [47]. The expression of P2Y4 is associated with inflammatory injury in tubular cells in sepsis-AKI. P2Y4 knockdown ameliorates sepsis-induced kidney injury in mice by inhibiting the NF-κB/MMP-8 axis activation [48].

Table 2 Expression of GPCRs related to renal intercellular stress in mouse

Gene_symbol	Glomeruli	PTS1	PTS2	PTS3	DTL1	DTL2	DTL3	ATL	MTAL	CTAL	DCT	CNT	CCD	OMCD	IMCD	
P2rx1	104.5	0.1	0	0	2.4	0.9	0.6	1.1	0.7	0.2	0	0.2	0.1	0.5	0.2	
P2rx2	6.8	0.1	0.1	0	0.5	0.3	0.4	0.1	0.3	0.1	0.1	0.1	0	0.3	0	
P2rx3	13.1	2.8	0.5	0.2	15.5	11.3	14	15.5	1	1	0.8	0.5	1	8.4	3.3	
P2rx4	212.4	48.6	95.3	53.6	55	52.6	52.3	70.6	27.8	39	81.1	87.4	77.5	61.8	57.1	
P2rx5	0.6	0.4	18.3	16	1.2	0.1	0.4	15.5	45.7	50	1.3	0.1	0.1	0.1	0	
P2rx6	2.4	0.9	0	0	1.6	0.4	0.9	0.6	0	0.1	0	0.2	0.2	0.4	0.1	
P2rx7	22.5	0.5	0.3	0	13.1	2.9	3.3	3.2	1	1.5	1	0.9	1.5	2.4	1	
P2ry1	75.1	3.6	3.4	1.1	0.9	0.4	0.8	0.1	1.2	0.6	4.1	7.9	2.1	0.3	0.2	
P2ry10	0.3	0	0	0	0	0.1	0	0	0	0	0	0	0	0	0	
P2ry10b	4.4	0.2	0.1	0	3.8	2.1	0.9	0	0.2	0.6	0.5	0.4	0.4	0.5	0	
P2ry12	0.8	0.1	0	0	0.1	0.5	0.2	0	0	0.3	0.1	0.2	0.1	0.4	0.2	
P2ry13	0.9	0.1	0	0	1	0.1	0.4	0.3	0.2	0.2	0.1	0.1	0	0.3	0.3	
P2ry14	8.2	0.9	0.1	0	9.6	1.4	3.8	2.3	0.3	0.3	2.9	20.5	53.9	236.5	146	
P2ry2	7.9	0.4	7.6	5.3	23.4	89.1	102.3	22.2	54.1	36	2.6	8.7	19.4	34.8	16.7	
Adora1	10.6	0.4	0.1	0	32.6	190.2	163.3	62.7	0.7	0.9	0.3	15.5	37.8	149.9	96.2	
Adora2a	10.3	0.2	0.1	0.1	3.8	2.1	2.4	3.4	2	0.6	0.2	0.2	0.2	1	1.1	
Adora2b	2.9	0.8	3.6	3.5	0.7	0.3	0.8	4.7	0.4	9.9	15.7	3	2.2	0.4	0.4	
Adora3	3.5	0.5	0	0	7.4	1.1	2.4	2	0.1	0.1	0	0.1	0	1	0.2	
Lpar1	3.2	0.5	0.3	0	4.6	0.8	4.7	12.4	1	2.4	3.3	3.9	8.7	20.8	22.7	
Lpar2	0.2	0.3	0.4	0.6	1.1	0.3	0.3	0.3	0.1	0.2	0.2	0.2	0.2	0.3	0.3	
Lpar3	1.5	94	26.4	19.9	1.5	0.2	0.6	0.2	0	0	0.3	0.1	0.1	0.1	0	
Lpar4	3.9	0.1	0	0	3.7	1.8	0.5	1.2	0.1	0.2	0.3	0.8	0.4	0.7	0.1	
Lpar5	1.3	0.1	0	0	0.8	1.8	8	5.8	0	0.2	0.1	0.2	0.2	0.7	0.1	
Lpar6	8.8	4.1	12.5	15.2	6	4.5	6.2	2.6	3.2	4.8	5.8	7.2	7.9	3	4.6	
S1pr1	95.7	1.1	1.1	1.7	36.3	20.9	22.1	3.7	3	5.8	4.6	5.6	2.2	6.2	1.8	
S1pr2	14.5	1.2	1	1	7.7	4	6	2.7	0.8	1.2	1.2	2	2.4	2.8	0.2	
S1pr3	219.3	0.2	0.1	0.2	8.2	2	3.3	3.8	2.8	1.1	0.4	13.7	21.8	1.4	0.6	
S1pr4	4.5	0.2	0.1	0.1	3.3	1.8	1.4	2.5	0.2	0.2	0.2	0.2	0.1	1.3	0.2	
S1pr5	4.1	0.4	0	0	2.8	1.1	2.1	0.8	0.2	0.1	0.1	0.2	0.1	1	0.1	
Gpbar1	8.6	1.3	0.2	0.2	13.6	3.6	4	6.5	0.1	0.2	0.2	0.7	1.2	4.2	0.6	
Ffar1	1.1	0.2	0	0	2.6	0.8	0.9	1.2	0	0	0	0	0.1	0.5	0.1	
Ffar2	1.0	0.1	0	0	0.9	0.2	1.8	0.1	0	0	0	0.1	0.3	0.6	0.3	
Ffar3	1.0	1.4	1.7	0	1.4	0.3	0.3	0	0	0	0	0	0	0.1	0.1	
Ffar4	1.1	0	0	0	4	0.3	0.3	0.8	2.4	2.5	0.1	0	0.1	0.4	0.1	
The expression of GPCRs mentioned above is extracted from the database providing the mean gene expression values (transcripts per million, TPM) for micro-dissected mouse renal glomeruli (https://esbl.nhlbi.nih.gov/MRECA/G/) and tubule segments (https://esbl.nhlbi.nih.gov/MRECA/Nephron/). GlOM, glomerulus; PTS1, the initial segment of the proximal convoluted tubule; PTS2, the proximal straight tubule in cortical medullary rays; PTS3, the last segment of the proximal straight tubule in the outer stripe of outer medulla; DTL1, the short descending limb of the loop of Henle; DTL2, the long descending limb of the loop of Henle in the outer medulla; DTL3, the long descending limb of the loop of Henle in the inner medulla; ATL, the thin ascending limb of the loop of Henle; MTAL, medullary thick ascending limb of the loop of Henle; CTAL, cortical thick ascending limb of the loop of Henle; DCT, the distal convoluted tubule; CNT, the connecting tubule; CCD, cortical collecting duct; OMCD, outer medullary collecting duct; IMCD, inner medullary collecting duct

Adenosine is an important signaling molecule with a protective role in various physiological processes. Its action is mediated through four different adenosine receptors [49, 50]. Adenosine receptors belong to class A GPCRs. Their expression in the mouse and human kidney is shown in Table 2 and Supplementary Table 2, respectively. However, adenosine has a short half-life under normal physiological conditions due to rapid removal by nucleotidases, adenosine kinase, and adenosine deaminase. Hypoxia disrupts several key enzymes involved in adenosine production and degradation, leading to an overall increase in extracellular adenosine levels [51]. Adenosine receptors are expressed in innate immune cells such as macrophages, dendritic cells, and natural killer cells [52]. The activation of different subtypes of adenosine receptors (A1AR, A2aAR, A2bAR, and A3ARs) regulates various cellular responses [53, 54]. A1AR and A2AR are high-affinity adenosine receptors, while A2BR and A3R are 100-fold lower affinity for adenosine than A1AR. Studies have shown that A1AR activation upregulates the protective factor IL-11 through activation of ERK and hypoxia-inducible factor 1-α, as well as induces cytoprotective heat shock protein 27 (HSP27) synthesis through p38 MAPK activation phosphorylation, thereby reducing renal tubular apoptosis and inflammation [51]. Moreover, in mouse models of sepsis-AKI, the absence of A1aR resulted in a more rapid decline in GFR, indicating the importance of A1AR in regulating renal function [55]. Macrophage A2AR activation reduces inflammatory cell infiltration [56],exerting a renoprotective effect. These protective effects are dependent on receptors on bone marrow-derived immune cells rather than receptors on renal intrinsic immune cells [57]. Furthermore, in IRI mice, renal endothelial A2AR activation not only increases medullary blood flow and oxygen partial pressure, but also decreases medullary transport activity, mediating the protective effects of nuclear transporter protein 1ENT1 inhibitor [58].

Lysophospholipid receptors(LPAR/S1PR)

Phospholipids are the main components of biological membranes and usually have two fatty acid chains. Phospholipids with a single fatty acid are called lysophospholipids. Lysophospholipids, such as lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P), are produced by the metabolism and perturbation of biological membranes. Both molecules are established extracellular lipid mediators that signal through specific G protein-coupled receptors and have important roles in cellular stress signaling, inflammation, resolution, and host defense responses [59].

LPA receptors belong to GPCR class A subfamily, often been activated classically and trigger G-protein dependent signaling (Supplementary Table 1), and their expression in mouse and human kidney are shown in Table 2 and Supplementary Table 2, respectively. It can be divided into two subgroups based on their different protein homologies. LPAR1-3 are homologous to protein sequences in the endothelial differentiation gene (Edg) family [60], and LPAR4-6 are homologous to the sequences of P2Y purinergic receptor protein( LPA4 / GPR23 / P2Y9, LPA5 / GPR92 and LPA6 / P2Y5) [61]. Here we focus on LPAR1-3. The role of LPA depends on the exact receptor being activated. Accordingly, in IRI mouse model, simultaneous blockade of LPA1 and LPA3 receptors improves renal function, and the protective effect of the dual antagonist is reversed after the use of OMPT, an LPA3 agonist, suggesting that LPAR3 activation may promote renal injury in IRI [62]. Other findings suggest that the ligand LPA exerts a protective effect in the kidney [63, 64], but no study investigates the specific LPA receptor that this beneficial effect is based on [64]. Another study found that in IRI rats, LPA1 receptors promote the production and secretion of the pro-fibrotic factor PDGFB/CTGF in proximal tubular cells through EGFR/ERK1/2/AP-1 signaling [65]. Collectively, LPAR3 may have an important role in the acute phase of AKI injury while LPAR1 promotes the AKI to CKD fibrotic process.

Sphingosine 1-phosphate (S1P) is a naturally occurring lysophospholipid that is present at high nanomolar (nm) concentrations in serum [66]. S1P activates S1P receptors(S1PR), also belong to class A GPCR (Supplementary Table 1), to regulate a variety of important cellular functions, including cell survival, cytoskeletal rearrangement, and cell motility [67]. In kidney, S1PR1 and S1PR2 are expressed in proximal tubular cells, endothelial cells, and immune cells [68, 69]. Also, they are the major S1P receptors expressed in the embryonic kidney. S1PR1 expression increases during kidney development, while S1PR2 expression decreases [70]. In renal IRI, S1P provides functional and structural protection through S1PR1 by maintaining endothelial barrier function, reducing apoptosis and promoting regeneration by increasing angiogenesis and proliferation [71]. S1PR2 activation promotes apoptosis and proinflammation through Rho kinase and ROCK1 activation [72]. S1P3 and S1P4 receptors play a central role in the initiation of the immune response. S1PR3 is essential for dendritic cell function and NKT cell activation, while S1PR4 exerts anti-inflammatory by increasing IL-10 release and inhibiting T cell proliferation through the IL-2 / IFNγ pathway [73, 74]. The nonspecific S1PR agonist FTY720 alleviates cisplatin induced kidney injury by enhancing proximal tubular cell mitochondrial function [75]; and regulates mitochondrial biogenesis in DCs to prevent kidney from ischemic reperfusion injury [76]. Oral fingolimod is an S1PR modulator that has been approved by the FDA for the treatment of relapsing multiple sclerosis. Considering the immune-regulating effect and renal tubular protective effects, S1P and its receptors are thought to have therapeutic potential in AKI. The use of fingolimod in a clinical phase II trial in renal transplantation improved creatinine levels but, unfortunately, the increased incidence of macular edema limited the advancement of the trial [77, 78].

Bile acid receptors

Bile acids, the major organic constituents of bile, are mainly several structurally similar steroidal acids. In addition to hepatic and intestinal fat absorption, circulating bile acids regulate a wide range of metabolic pathways, including glucose and lipid metabolism regulation, energy expenditure, and immune responses by activating bile acid receptors, acting as signaling molecules. There are two main bile acid receptors in the kidney: the nuclear receptor farnesoid X receptor (FXR) and the G protein-coupled bile acid receptor 1 (GPBAR1, also known as TGR5) [79, 80]. TGR5 belong to class A GPCRs (Supplementary Table 1), and its expression in kidney is shown in Table 2 (mouse). Previous studies have mostly focused on TGR5 in diabetes/obesity-related renal inflammation and fibrosis. But the protective role of TGR5 activation in IRI kidneys has recently been found. Farnesiferol B could protect kidney function from I/R-induced damage by attenuating inflammation through activating TGR5 in macrophages [81]. Renal tubular TGR5 activation increased renal AQP2 expression and ameliorated lithium-induced uremia, which was reversed in TGR5 knockout mice, suggesting that TGR5 is involved in regulating renal water metabolism [82]. Besides, activation of TGR5 by lithocholic acid (LCA) in collecting duct master cells is found to ameliorate IRI-induced loss of aquaporin-2 (AQP2) through upregulation of hypoxia-inducible factor HIF-1α; also, it may directly inhibit NF-kB pathway and attenuate renal inflammation [83]. Nevertheless, studies on TGR5 receptors in kidneys are currently limited. Considering that its ligand originates from the hepatic-intestinal circulation, whether the role of that intestinal flora metabolites in AKI is associated with TGR5 needs further investigation.

Fatty acids receptors

Fatty acids serve as both energy substrates and signaling molecules in various biological processes. Long- and medium-chain fatty acids obtained from dietary triglycerides, as well as short-chain fatty acids (SCFAs) produced from fermentation of indigestible dietary fibers by intestinal microorganisms, are the primary sources of free fatty acids (FFAs) in the metabolic network. Emerging evidence suggests that FFAs not only provide energy, but also act as signaling molecules that link metabolism and immunity through free fatty acid receptors (FFARs), which are class A GPCRs with classical signaling (Supplementary Table 1). The expression of FFARs in kidney are shown in Table 2 (mouse). FFAR4, for example, is downregulated in cisplatin-induced acute kidney injury (AKI), and the FFAR4 agonist TUG891 has been shown to effectively alleviate injury by regulating endoplasmic reticulum stress-related apoptosis [84]. Knockdown of FFAR4 systemically or specifically in renal tubular epithelial cells exacerbates AKI injury, while activation of renal tubular FFAR4 with TUG891 ameliorates cisplatin-induced renal tubular cell senescence through the Gq subunit of CaMKKβ/AMPK signaling [85]. Furthermore, FFAR4 (GPR120) is expressed in macrophages, and activation of GPR120 on macrophages has been shown to alleviate renal fibrosis in rat models of unilateral ureteral obstruction when autologously returned to the kidney via intrarenal injection in rat [86].

GW9508, the FFAR1(GPR40) agonist, reduced cisplatin-induced apoptosis in human renal proximal tubular epithelial HK-2 cells [87]. PBI-4050, a synthetic analogue of medium-chain fatty acids that not only agonizes GPR40 but also antagonizes the synthetic ligand of GPR84, has been found to be able to ameliorate renal fibrosis in three types of kidney disease (unilateral ureteral obstruction, ischemic reperfusion injury, and adenine-induced chronic kidney disease) [88]. PBI-4050 ameliorates renal fibrosis by ameliorating adenine-induced endoplasmic reticulum (ER) stress and apoptosis, which was reversed after GPR40 knockdown [89].

Cellular stress

Cannabinoid receptors

Anandamide (AEA) and 2-arachidonoylglycerol (2-AG) are essential components of the endogenous cannabinoid system, and are considered to be major ligands for CB1R and CB2R. CB1R and CB2R are class A GPCR (Supplementary Table 1), and their expression in kidney are shown in Table 3 (mouse). CB1R has a high affinity for AEA, while CB2R preferentially binds to 2-AG. These compounds are synthesized from lipid precursors on demand, act locally in an autocrine or paracrine manner, and are rapidly degraded [90]. Activation of CB1R not only regulates cAMP levels via Gαs and Gαi proteins, but also modulates intracellular Ca2 + concentration through Gαq proteins. CB1R and CB2R are often co-expressed on the same or adjacent cells and exhibit antagonistic effects. CB1R activation promotes oxidative stress and inflammation, leading to apoptosis and fibrosis, whereas CB2R activation has anti-inflammatory effects and reduces inflammation-driven fibrosis. In cisplatin-induced AKI, endogenous cannabinoids promote inflammation and tubular cell death via CB1R activation and downstream MAPK signaling. However, these injuries can be reversed by CB1R knockdown [91]. Conversely, HU-308, a selective CB2R agonist, ameliorates cisplatin-induced injury by reducing inflammation, oxidative stress, and renal cell death. CB2R knockdown, on the other hand, exacerbates cisplatin-induced renal inflammation and tissue damage [92]. Additionally, URB602, an enzyme that generates 2-AG, plays a protective role in renal ischemia-reperfusion injury (IRI) by scavenging ROS and reducing inflammatory mediators via CB2R in rat [93]. Notably, a common hydrolysis product of endogenous cannabinoids is arachidonic acid (AA), which can generate PGE2 through a series of enzymatic reactions. PGE2 also affects renal perfusion and inflammatory regulation in renal IRI [94]. Whether there is a linkage between cannabinoid receptors and PGE2 receptors in the kidney requires further investigation.

Table 3 Expression of GPCRs related to renal cellular stress in mouse

Gene_symbol	Glomeruli	PTS1	PTS2	PTS3	DTL1	DTL2	DTL3	ATL	MTAL	CTAL	DCT	CNT	CCD	OMCD	IMCD	
Cnr1	1.4	0.2	0	0	1.6	0.6	0.6	1.2	0	0	0	0	0	0.5	0.1	
Cnr2	18.5	0.1	0.2	0	3.3	2.3	0.5	0.1	0.3	0.7	0.7	0.7	0.4	0.4	0.1	
Gpr55	0.5	0.1	0	0	0.7	0.1	0.1	0	0	0	0	0	0	0.1	0.1	
Adgra1	1.3	0.1	0	0	1.5	0.7	0.9	0.8	0	0	0	0	0	6.1	8.2	
Adgra2	10.8	2.8	0.2	0	2.4	0.4	1	0.4	0.2	0.1	0.1	0.1	0.1	0.4	0.1	
Adgra3	35.7	23.3	58.4	27.4	52.9	58.4	32.1	35	39.2	81.4	42.6	27.4	21.2	17.9	24.4	
Adgrb1	0.6	0.1	0	0	2.2	0.1	0.4	0.6	0	0	0	0	0	0.2	0.2	
Adgrb2	2.8	0.1	0	0	3.1	0.9	2.6	1.1	0	0	0.1	0.1	0.2	0.8	0.3	
Adgrb3	5.1	0.8	0	0	8.8	1.9	2.8	3.9	0	0.1	0.1	0.1	0.1	1.7	0.3	
Adgrd1	3.6	0.3	0.2	0.2	3.9	1.3	1.7	1	0.3	0.1	0.1	0.1	0.2	1.2	0.2	
Adgrd2-ps	0.1	0	0	0	0.1	0	0.1	0	0	0	0	0	0	0	0	
Adgre1	2.3	0.6	0.7	0	0.7	1.2	0.1	0.6	2.6	6.6	3.7	4.1	2.3	1.3	0	
Adgre4	4.8	0.1	0	0	0.4	0.3	0.4	0.4	0	0.4	0.2	0.1	0.1	0.1	0	
Adgre5	421.6	1.5	51.9	24.5	35.1	18.3	10.3	120.4	6	8.2	6	18.8	28.1	37	6.6	
Adgrf1	0.5	0.2	0	0	0.8	0.1	0.6	1.2	0	0	0.5	0.4	0.2	3.2	121.6	
Adgrf2	2.6	0.2	0	0.1	1.6	2.7	1.2	2.1	0	0.1	0	0.1	0.1	1	0.1	
Adgrf3	1.5	0.2	0.1	0	3.2	1.4	1.2	3.7	0.1	0.1	0	0.2	0.2	1.3	0.2	
Adgrf4	0.6	0.1	0	0	1.2	0.3	0.1	0.1	0.1	0.1	0	0.1	0.1	0.2	0.2	
Adgrf5	231.2	1	2.5	3.7	111.3	70.6	51.2	13.3	8.5	12.1	48	155.4	186.2	406	6.3	
Adgrg1	71.0	96.9	63.3	35.8	1054.9	830.1	1136.4	644.8	599.7	928.4	302.8	1055.3	1304	1242	187.2	
Adgrg2	0.7	0.4	0.3	0	0.8	0.4	0.7	0.3	0	0.1	0.1	3	3.9	0.3	0	
Adgrg3	10.9	0.3	0.2	0.9	25.9	15.8	15.1	15.9	2.8	3.6	1.7	16.6	12.4	10.6	2.5	
Adgrg4	1.0	1.8	7	13.1	1.6	0.5	0.7	0.2	0	0	0	0	0.1	0.1	0	
Adgrg5	0.9	0	0	0	0.2	0.1	0.2	1.6	0	0.1	0.1	0.1	0.1	0.1	0.1	
Adgrg6	5.3	0.1	0	0	31.1	0.8	8	0.4	0.1	0.2	0.1	5.3	12.2	17.2	8.6	
Adgrg7	0.3	0	0	0	0.2	0.3	0.3	0.1	0	0	0	0	0	0.1	0	
Adgrl1	8.6	6.8	2.3	1.8	7.1	2.9	2.4	3.5	1.4	2.1	1.4	2.7	3.3	3.9	2	
Adgrl2	112.0	6	13.1	3.6	38.6	20.5	14.8	9.7	18.9	21.2	16.8	11	13.8	22.7	1	
Adgrl3	27.3	1.7	0	0	22.6	5.4	7.9	8	0.2	0.3	0.1	0.1	0.3	3.3	1	
Adgrl4	158.9	4.1	3	6.7	261.2	173.7	59.4	9.5	14.8	18.5	23.7	20.9	13.7	43.2	1.6	
Adgrv1	9.1	1.1	0.2	0.4	34.7	6.6	7.2	3.6	0.8	0.4	0.1	0.8	1.4	1.9	0.6	
The expression of GPCRs mentioned above is extracted from the database providing the mean gene expression values (transcripts per million, TPM) for micro-dissected mouse renal glomeruli (https://esbl.nhlbi.nih.gov/MRECA/G/) and tubule segments (https://esbl.nhlbi.nih.gov/MRECA/Nephron/). GlOM, glomerulus; PTS1, the initial segment of the proximal convoluted tubule; PTS2, the proximal straight tubule in cortical medullary rays; PTS3, the last segment of the proximal straight tubule in the outer stripe of outer medulla; DTL1, the short descending limb of the loop of Henle; DTL2, the long descending limb of the loop of Henle in the outer medulla; DTL3, the long descending limb of the loop of Henle in the inner medulla; ATL, the thin ascending limb of the loop of Henle; MTAL, medullary thick ascending limb of the loop of Henle; CTAL, cortical thick ascending limb of the loop of Henle; DCT, the distal convoluted tubule; CNT, the connecting tubule; CCD, cortical collecting duct; OMCD, outer medullary collecting duct; IMCD, inner medullary collecting duct

In addition to CB1R and CB2R, cannabinoids can activate many other GPCRs in vivo, such as GPR55, which are classified as members of the novel cannabinoid receptor family [95]. Studies have shown that antagonists of GPR55 can significantly alleviate sepsis-induced renal injury, embodying as reducing KIM-1, NGAL, creatinine and urea nitrogen levels [96].

Adhesion-like G protein-coupled receptors (aGPCRs)

aGPCRs, class B2 GPCRs, are the second largest GPCR subfamily after the retinoid family, and they consist of nine subclasses (I to IX), including 33 members. These receptors have a distinct structure with a long extracellular N-terminal and a self-hydrolysis site known as the GPS motif that enables their self-activation without ligand binding. Their expression in kidney are shown in Table 3 (mouse) and Supplementary Table 2 (human). aGPCRs are widely expressed in vivo and have been implicated in various biological processes, such as inflammation [97] and cell proliferation [98]. The activation of aGPCRs and their downstream signaling pathways are involved in several physiopathological processes, but their role in the pathogenesis of AKI is still limited.

Among the aGPCRs, Gpr116 is one of the most abundant in the kidney and is closely associated with H + secretion in the renal collecting duct, regulating ATPase transport and urinary acidification. Knockdown of Gpr116 causes enhanced tubular H + secretion and leads to tubular alkalosis [99]. ELTD1-Gpr116 double-knockout mice develop severe glomerulosclerotic lesions, and 80% of double-knockout mice do not survive past eight weeks [100]. Furthermore, Gpr97 expression is upregulated in kidneys of AKI mice and patients with acute tubular necrosis. Systemic knockout of Gpr97 in mice, compared to wild-type mice, showed significantly less renal injury and inflammation. Gpr97 activation increases sema3A expression by upregulating the RNA-binding protein HuR, which enhances sema3A stability and participates in AKI tubular apoptosis and inflammation [101].

Despite recent advancements in elucidating the crystal structure of aGPCRs, most of these receptors are orphan receptors. Their relatively high expression in kidneys and unique ability to self-hydrolyze for cleavage activation suggests a potential role in kidney physiology and pathology. Further investigation is warranted to unravel the precise role of aGPCRs in the kidney.

Inflammation and immune responses

Chemokine receptor

Chemokines are a diverse group of cytokines that play a vital role in the recruitment of leukocytes during both acute and chronic inflammation. There are four subfamilies of chemokines, including CCL, CXCL, CX3CL, and CL, which bind to a total of 19 known class A GPCRs [102]. Their expression in mouse and human kidney are shown in Table 4 and Supplementary Table 2, respectively. The importance of the chemokine family in AKI has been extensively reviewed [11, 103–105]. Depending on their cell-specific expression, chemokine receptors play distinct roles in AKI pathogenesis. For instance, neutrophils primarily bind to chemokines CXCL1, CXCL8, and others via CXCR1 and CXCR2 receptors on their surface, whereas monocytes and macrophages mainly bind to chemokines CCL2, CCL8, and others via membrane surface CCR1, CCR2, and CCR5 receptors, leading to various signaling pathways that contribute to AKI injury.

Table 4 Expression of GPCRs related to renal inflammation and immune responses in mouse

Gene_symbol	Glomeruli	PTS1	PTS2	PTS3	DTL1	DTL2	DTL3	ATL	MTAL	CTAL	DCT	CNT	CCD	OMCD	IMCD	
Ccr1	3.0	0.2	0	0	2.5	1	1	0.4	0.1	0.3	0.1	0.1	0.1	0.8	0.1	
Ccr10	0.7	0	0	0	1.3	0.5	0.5	0	0.2	0.2	0.6	0.6	0.6	0.3	0.1	
Ccr1l1	0.8	0.1	0	0	0.6	0.3	0.4	0.6	0	0	0	0	0.1	0.4	0.1	
Ccr2	7.8	0.5	0.1	0	4.2	1.3	2.2	1	0.1	3.8	2.3	1.6	1	0.6	0.2	
Ccr3	0.4	0	0	0	0.4	0.1	0.4	0	0	0	0	0	0	0.2	0	
Ccr4	3.6	0.5	0	0	6.6	1.5	2.5	3.7	0.1	0.1	0.1	0.3	0.2	2.2	0.3	
Ccr5	1.1	0.2	0.2	0	1.9	0.7	1.4	1.1	0.7	1.7	0.6	1	0.7	0.4	0	
Ccr6	2.7	0.9	0.3	1.2	5.5	2.6	2.8	2.3	0	0	0	0.1	0	0.9	0.2	
Ccr7	4.7	0.1	0	0	1.9	0.9	1	0.5	0	0	0	0	0	0.2	0.3	
Ccr8	3.4	0.5	0	0	4.4	0.9	1.9	0.9	0.1	0	0	0	0	0.8	0.1	
Ccr9	4.1	0.7	0.1	0.3	7.4	2.1	3.5	2.7	0.1	0.1	0.1	0.1	0.2	1.4	0.4	
Ccrl2	133.5	1.3	1.3	0.5	12	9.9	2.6	0.6	1.4	6.1	6.1	6.2	2.4	2.2	0.3	
Cmklr1	6.6	0.2	0	0.1	18.8	2	1.1	0	0.1	0.2	0.1	0.2	0.2	0.6	0.5	
Cx3cr1	6.3	0.5	0.5	0	3	0.9	1.1	2	2.1	6	2.3	2.7	2.1	1.2	0.2	
Cxcr1	0.3	0.1	0	0	0	0.2	0.1	0	0	0	0	0	0	0	0	
Cxcr2	3.0	0.2	0	0	2.7	1	2.4	0.9	0	0	0	0	0.1	0.2	0.1	
Cxcr3	0.7	0.1	0	0	0	0.2	0.1	0	0	0.4	0.2	0.3	0.2	0.1	0	
Cxcr4	4.5	0.2	0	0	2.5	0.6	4.8	0.2	0.1	1	1	3.6	2.8	0.5	0.2	
Cxcr5	1.5	0	0	0	1.6	0.3	0.9	0.1	0	0	0	0	0	0.5	0.1	
Cxcr6	1.6	0.2	0.1	0	1.7	1.2	2.1	1.5	0.2	0.7	0.2	0.3	0.4	0.3	0.4	
Xcl1	0.3	0.1	0	0	0.1	0	0.1	0.2	0	0.1	0	0.1	0	0.2	0	
Xcr1	1.9	0.1	0	0	0.7	0.4	0.7	0.2	0	0.1	0	0.2	0.1	0.2	0	
C3ar1	3.0	0.6	0.1	0	3.9	1	1.7	1.6	0.7	1.6	0.8	0.9	0.6	1.2	0.2	
C5ar1	3.9	0.6	0.3	0.1	5.5	3	1.6	2.3	2	2.9	0.9	1.1	0.8	2.3	0.3	
C5ar2	3.4	0.3	0	0	5	1.2	2.7	1.7	0.2	0.1	0.1	0.1	0.1	0.8	0.4	
The expression of GPCRs mentioned above is extracted from the database providing the mean gene expression values (transcripts per million, TPM) for micro-dissected mouse renal glomeruli (https://esbl.nhlbi.nih.gov/MRECA/G/) and tubule segments (https://esbl.nhlbi.nih.gov/MRECA/Nephron/). GlOM, glomerulus; PTS1, the initial segment of the proximal convoluted tubule; PTS2, the proximal straight tubule in cortical medullary rays; PTS3, the last segment of the proximal straight tubule in the outer stripe of outer medulla; DTL1, the short descending limb of the loop of Henle; DTL2, the long descending limb of the loop of Henle in the outer medulla; DTL3, the long descending limb of the loop of Henle in the inner medulla; ATL, the thin ascending limb of the loop of Henle; MTAL, medullary thick ascending limb of the loop of Henle; CTAL, cortical thick ascending limb of the loop of Henle; DCT, the distal convoluted tubule; CNT, the connecting tubule; CCD, cortical collecting duct; OMCD, outer medullary collecting duct; IMCD, inner medullary collecting duct

Complementary receptor

Complement activation is a crucial component of innate immunity, generating biologically active fragments (such as C3a, C5a, and C3b) that exert diverse effects through interactions with their respective receptors. C5aR1 and C3aR1 are class A GPCRs (Supplementary Table 1), expressed not only on myeloid cells (e.g., neutrophils, monocytes/macrophages, mast cells) but also on some non-myeloid cells (e.g., endothelial cells, tubular epithelial cells) [106]. Their expression in mouse and human kidney are shown in Table 4 and Supplementary Table 2, respectively. In acute kidney injury, C3a and C5a deposition is increased in the kidney, and attenuating C3aR and/or C5aR expression can ameliorate renal ischemia-reperfusion injury, although C5a seems to play a more predominant role in the pathogenesis of this injury [107]. The important role of complement in renal disease has been thoroughly reviewed previously [106, 108–110]. Notably, the roles of C5aR and C3aR differ in urinary tract infections. In the uropathogenic E. coli (UPEC) model, C5a activates C5aR on renal tubules, promoting bacterial adhesion and colonization by affecting the exposure of mannose sites on tubular cells, while also promoting the release of inflammatory factors and amplifying inflammation [111, 112]. In contrast, the C3a/C3aR1 signaling pathway exhibits a nephroprotective role in urinary tract infections. In the UPEC model, C3a activates C3aR on macrophages, down-regulating inflammatory factors, enhancing macrophage phagocytosis, and reducing bacterial load and renal tissue damage [113].

Therapeutic potential of GPCRs and ligands in AKI

Numerous animal studies have demonstrated the therapeutic potential of targeting GPCRs in AKI. As such, this section will delve into the clinical translation and potential application of GPCRs and their ligands in the treatment of AKI.

Angiotensin is a crucial component of the RAS system in vivo, and its inhibitory agents such as losartan, targeting the AT1R receptor, are widely used in the clinical management of blood pressure. While the use of ARBs was previously discontinued during AKI clinical practice, recent clinical studies have shown that timely initiation of ARBs after the acute phase can improve the prognosis of patients with AKI. A dual-center parallel cohort study conducted in Sweden and the UK, which included 7303 hospitalized AKI patients with a median follow-up of 1.1 years, demonstrated that continuing previous ACEI/ARB therapy after an AKI episode did not increase the risk of heart failure and recurrent AKI compared to discontinuers [114]. Similar results were found in a Taiwan cohort of Asian patients with AKI/AKD requiring dialysis, which included 17,141 patients with a mean follow-up of 1.23 years. Patients who continued ARB treatment after withdrawal from dialysis apparatus had a lower risk of all-cause mortality and no increased risk of re-dialysis compared to those who did not use ARB [115]. It is important to note that the use of ACEI/ARB is not recommended in the acute phase of AKI; rather, fluid supplementation and vasopressors are preferred to improve the patient’s circulating blood volume. However, the most effective vasopressor for treating general shock or specific AKI remains unclear [116]. Currently, six ongoing clinical trials investigated the efficacy of angiotensin II in AKI from various causes, such as sepsis and post-liver transplantation. For instance, a study comparing angiotensin II with standard therapy (midodrine, octreotide, and albumin) to improve renal injury in patients with hepatorenal syndrome is still in the patient recruitment or pre-recruitment phase (see Table 5). Concerning ligands, Ang [1–7] is a critical member of the hypotensive axis of the RAS system (Ang 1–7/ ACE2/MasR). Wagener et al. [117]. conducted an RCT study (n = 22, including patients with COVID-19) to investigate the effect of recombinant protein TXA-127 on AKI in critically ill patients. The results indicated that TXA-127 was safe to use in patients with severe COVID-19 infection and that the incidence of AKI was low. Nevertheless, larger studies are needed to provide more substantial evidence on this issue.

Table 5 Pharmacological agents targeting GPCR ligands currently reported to be in clinical trials of AKI

NCT number	Product Name	Class	Status	Study Phase	Conditions	Interventions	Locations	
NCT00711789	Angiotensin II	Angiotensin II	Unknown status	Phase 2	Acute Renal Failure|Sepsis|Septic Shock	Drug: Angiotensin II|Drug: Saline placebo	Northern Hospital, Epping, Victoria, Australia|The Western Hospital, Footscray, Victoria, Australia	
NCT04592744	Angiotensin II	Angiotensin II	Enrolling by invitation	Phase 4	Cirrhosis, Liver|End Stage Liver DIsease|Acute Kidney Injury|Liver Transplant; Complications	Drug: Angiotensin II|Drug: Norepinephrine	Michael Y Lin, Los Angeles, California, United States	
NCT04901169	Angiotensin II	Angiotensin II	Recruiting	Phase 2	Liver Transplant; Complications|Vasoplegia	Drug: Angiotensin II|Drug: Saline	University of California, San Francisco, San Francisco, California, United States	
NCT05475717	Alprostadil	PGE1	Recruiting	Phase 2	Contrast-induced Acute Kidney Injury	Drug: Alprostadil liposome injection	Beijing University First Hospital, Beijing, Beijing, China	
NCT03892447	Alprostadil	PGE1	Unknown status	Phase 4	Children AKI Patients	Drug: Alprostadil|Drug: Sodium Ferulate|Drug: Dopamine	Shenjing Hospital, Shenyang, Liaoning, China	
NCT01722513	Alprostadil	PGE1	Unknown status	Phase 4	Kidney Diseases|Diabetes Mellitus|Acute Kidney Injury|Kidney Failure, Chronic|Renal Insufficiency	Drug: Alprostadil & control	Department of Cardiology, Shanghai Tenth People’s Hospital, Shanghai, Shanghai, China	
NCT05524051	TIN816	Recombinant human CD39 enzyme	Recruiting	Phase 2	Acute Kidney Injury Following Cardiac Surgery	Drug: TIN816|Other: Placebo	Unknown	
NCT04570397	Ravulizumab	humanized monoclonal antibody that inhibits complement C5	Active, not recruiting	Phase 3	Covid19|Thrombotic Microangiopathies|Acute Kidney Injury	Drug: Ravulizumab	Brigham and Women’s Hospital, Boston, Massachusetts, United States	
NCT04743804	Ravulizumab	humanized monoclonal antibody that inhibits complement C5	Terminated	Phase 3	Thrombotic Microangiopathy	Biological: Ravulizumab|Other: Placebo|Other: Best Supportive Care	Clinical Trial Site, Tucson, Arizona, United States|Clinical Trial Site, Orange, California, United States|Clinical Trial Site, Gainesville, Florida, United States|Clinical Trial Site, Lexington, Kentucky, United States|Clinical Trial Site, Boston, Massachusetts, United States|Clinical Trial Site, Boston, Massachusetts, United States|Clinical Trial Site, Boston, Massachusetts, United States|Clinical Trial Site, New York, New York, United States|Clinical Trial Site, Valhalla, New York, United States|Clinical Trial Site, Cleveland, Ohio, United States|Clinical Trial Site, Columbus, Ohio, United States|Clinical Trial Site, Philadelphia, Pennsylvania, United States|Clinical Trial Site, Pittsburgh, Pennsylvania, United States|Clinical Trial Site, Salt Lake City, Utah, United States|Clinical Trial Site, Morgantown, West Virginia, United States|Clinical Trial Site, Bruxelles, Belgium|Clinical Trial Site, Leuven, Belgium|Clinical Trial Site, Liege, Belgium|Clinical Trial Site, Montreal, Canada|Clinical Trial Site, Toronto, Canada|Clinical Trial Site, Bordeaux, France|Clinical Trial Site, Chambery, France|Clinical Trial Site, Lille, France|Clinical Trial Site, Montpellier, France|Clinical Trial Site, Paris, France|Clinical Trial Site, Tours, France|Clinical Trial Site, Bergamo, Italy|Clinical Trial Site, Rome, Italy|Clinical Trial Site, Iruma-gun, Japan|Clinical Trial Site, Miyagi, Japan|Clinical Trial Site, Miyazaki City, Japan|Clinical Trial Site, Nagoya, Japan|Clinical Trial Site, Osaka, Japan|Clinical Trial Site, Sapporo, Japan|Clinical Trial Site, Shinjuku-ku, Japan|Clinical Trial Site, Tokyo, Japan|Clinical Trial Site, Daegu, Korea, Republic of|Clinical Trial Site, Gwangju, Korea, Republic of|Clinical Trial Site, Seoul, Korea, Republic of|Clinical Trial Site, Amsterdam, Netherlands|Clinical Trial Site, Nijmegen, Netherlands|Clinical Trial Site, Barcelona, Spain|Clinical Trial Site, Granada, Spain|Clinical Trial Site, Madrid, Spain|Clinical Trial Site, Kaohsiung, Taiwan|Clinical Trial Site, Taichung, Taiwan|Clinical Trial Site, Taipei, Taiwan|Clinical Trial Site, Liverpool, United Kingdom|Clinical Trial Site, London, United Kingdom|Clinical Trial Site, Newcastle, United Kingdom|Clinical Trial Site, Nottingham, United Kingdom|Clinical Trial Site, Oxford, United Kingdom|Clinical Trial Site, Salford, United Kingdom	
Abbrevation: GPCR, G protein-coupled receptor; AKI, acute kidney injury; COVID-19, Corona Virus Disease 2019; PEG1,Prostaglandin E1

Prostaglandins (PGs) are hormone-like metabolites of arachidonic acid (AA) that act as both hormones and chemical signal modulators. They play important roles in various biological functions, including blood pressure regulation and fluid homeostasis. A double-blind, placebo-controlled randomized trial investigated the effect of prostaglandin E1 infusion on the prognosis of patients during the perioperative period of living liver transplantation. The study’s secondary endpoints included AKI. The results showed a significantly lower incidence of AKI in the PGE1 treatment group compared to the control group (8.2% vs. 28%; P = 0.02), as well as lower peak and mean postoperative creatinine levels. However, differences in other endpoints, such as the incidence of hepatic artery thrombosis, postoperative bleeding, in-hospital mortality, and post-transplant hospital stay, were not statistically significant between the two groups [118]. Currently, three clinical trials exploring the therapeutic efficacy and safety of the analog alprostadil (liposomes as drug carrier) in contrast-induced AKI and pediatric AKI are underway (Table 5).

Abnormal purine metabolism plays a crucial role in the development of AKI. Extracellular ATP (eATP) is metabolized by CD39 to AMP/ADP, which is further degraded by CD73 to adenosine. Platelet P2Y12 receptor antagonists, such as clopidogrel and prasugrel, are commonly used in clinical practice to prevent and treat thrombotic events associated with cardiovascular disease. In patients with renal insufficiency and acute coronary syndromes, P2Y12 inhibitors have been shown to significantly reduce patient mortality [HR 0.82, 95% CI 0.54–0.96; P = 0.006] and the risk of re-infarction (HR 0.53, 95% CI 0.30–0.95; P = 0.033) [119]. However, clinical studies targeting renal purinoceptors are limited. Purine metabolism intermediates, which act as GPCR ligands, have also garnered much attention in clinical research. Two clinical trials are currently underway to explore the efficacy and safety of recombinant human CD39 protein in post-operative cardiac AKI and septic AKI. However, these studies are still in their early stages.

The pathogenic role of complement C5 in acute kidney injury has been demonstrated at animal and clinical levels. Ravulizumab, a novel long-lasting C5 inhibitor, received FDA approval as the drug of choice for treating acute episodes of atypical hemolytic uremic syndrome (aHUS), characterized by the main clinical features of microangiopathic hemolytic anemia, acute kidney injury, and thrombocytopenia triad [120]. Another RCT showed that patients with severe COVID-19 often had AKI, and Ravulizumab treatment was effective in improving the overactivation of the complement cascade in patients with AKI, with a significant decrease in blood free C5 levels and a significant recovery of eGFR at 30 days of follow-up (P = 0.009). However, unfortunately, compared with the control group, patients in the Ravulizumab group had increased exposure to hemodialysis at day 30 (9% vs. 18%) [121]. Two additional clinical trials investigating the efficacy and safety of Ravulizumab in patients with AKI are ongoing (Table 5), and more research evidence is needed on the protective role of Ravulizumab in AKI, including AKI to CKD transition.

Conclusion and perspectives

AKI is a serious public health problem with high morbidity and mortality, and an in-depth understanding of the characteristics and pathogenesis of disease is an effective strategy to prevent and treat this disease. As mentioned above, GPCRs play an important role in both the repair after mild AKI injury and the progression of CKD after severe AKI injury. Moreover, there are many newly discovered promising GPCRs, such as cannabinoid receptors, fatty acid receptors, and lysophospholipid receptors, hold great potential for therapeutic intervention. Of note, the specificity of the tissue localization of target GPCRs in vivo needs to be taken into consideration in future clinical translation.

Although previous studies on GPCRs in AKI have mainly focused on post-injury hemodynamic changes, apoptosis, and inflammation, recent advances in technology, such as single-cell sequencing, ATAC analysis, and metabolomics, have led to the discovery of new pathogenic mechanisms, including immunometabolic reprogramming and iron death, which suggest that GPCRs may have additional roles and mechanisms in AKI. Moreover, the development of ultra-low temperature electron microscopy (cryo-EM) in crystallology has highlighted the advantages of GPCR signaling properties, such as biased signaling, in drug development, which could lead to improvements in existing drugs and reduction of side effects. Furthermore, these advancements provide new opportunities to identify and explore new therapeutic targets for the development of more effective drugs to improve the prognosis of AKI patients.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Material 1: Supplementary Table 1 Basic information of GPCRs. The explanation of class, activation mode and G signaling can be found in Figs. 1, 2 and 3.

Supplementary Material 2: Supplementary table 2 Expression of GPCRs in human kidney. The expression of GPCRs mentioned above is extracted from the Higgins Normal Tissue Panel dataset from Nephroseq database providing the gene expression by log2 median-centered ratio for human normal kidney tissue (https://www.nephroseq.org/). It contains 34 normal kidney samples from various kidney structures were analyzed on cDNA microarray.

Acknowledgements

Thanks for the researches grants from the National Key R&D Program of China [2022YFC2502500/2022YFC2502501], the Key Program of the Natural Science Foundation of China [No.82030023], the Natural Science Foundation of China [Nos.82322012, U22A20279, 81800616], Frontier specific projects of Xinqiao Hospital [No. 2018YQYLY004], Chongqing Graduate Innovation Program [CYB23291].

Author contributions

Liangjing Lv wrote the main manuscript text and prepared Figs. 1, 2 and 3. Yong Liu, Jiachuan Xiong, Shaobo Wang, Yan Li, Bo Zhang and Yinghui Huang analysed and interpretated the data. Jinghong Zhao designed and revised the study. All authors reviewed the manuscript.

Data availability

No datasets were generated or analysed during the current study.

Declarations

Competing interests

The authors declare no competing interests.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Kellum JA Romagnani P Ashuntantang G Ronco C Zarbock A Anders HJ Acute kidney injury Nat Rev Dis Primers 2021 7 1 52 10.1038/s41572-021-00284-z 34267223
Kellum JA, Romagnani P, Ashuntantang G, Ronco C, Zarbock A, Anders HJ. Acute kidney injury. Nat Rev Dis Primers. 2021;7(1):52.34267223 10.1038/s41572-021-00284-z
2. Ronco C Bellomo R Kellum JA Acute kidney injury Lancet 2019 394 10212 1949 64 10.1016/S0140-6736(19)32563-2 31777389
Ronco C, Bellomo R, Kellum JA. Acute kidney injury. Lancet. 2019;394(10212):1949–64.31777389 10.1016/S0140-6736(19)32563-2
3. Levey AS James MT Acute kidney Injury Ann Intern Med 2017 167 9 ITC66 80 10.7326/AITC201711070 29114754
Levey AS, James MT. Acute kidney Injury. Ann Intern Med. 2017;167(9):ITC66–80.29114754 10.7326/AITC201711070
4. Mehta RL Burdmann EA Cerda J Feehally J Finkelstein F Garcia-Garcia G Recognition and management of acute kidney injury in the International Society of Nephrology 0by25 Global Snapshot: a multinational cross-sectional study Lancet 2016 387 10032 2017 25 10.1016/S0140-6736(16)30240-9 27086173
Mehta RL, Burdmann EA, Cerda J, Feehally J, Finkelstein F, Garcia-Garcia G, et al. Recognition and management of acute kidney injury in the International Society of Nephrology 0by25 Global Snapshot: a multinational cross-sectional study. Lancet. 2016;387(10032):2017–25.27086173 10.1016/S0140-6736(16)30240-9
5. Insel PA Sriram K Gorr MW Wiley SZ Michkov A Salmeron C GPCRomics: An Approach to Discover GPCR Drug targets Trends Pharmacol Sci 2019 40 6 378 87 10.1016/j.tips.2019.04.001 31078319
Insel PA, Sriram K, Gorr MW, Wiley SZ, Michkov A, Salmeron C, et al. GPCRomics: An Approach to Discover GPCR Drug targets. Trends Pharmacol Sci. 2019;40(6):378–87.31078319 10.1016/j.tips.2019.04.001
6. Sriram K Insel PA G protein-coupled receptors as targets for approved drugs: how many targets and how many drugs? Mol Pharmacol 2018 93 4 251 8 10.1124/mol.117.111062 29298813
Sriram K, Insel PA. G protein-coupled receptors as targets for approved drugs: how many targets and how many drugs? Mol Pharmacol. 2018;93(4):251–8.29298813 10.1124/mol.117.111062
7. Hauser AS Attwood MM Rask-Andersen M Schioth HB Gloriam DE Trends in GPCR drug discovery: new agents, targets and indications Nat Rev Drug Discov 2017 16 12 829 42 10.1038/nrd.2017.178 29075003
Hauser AS, Attwood MM, Rask-Andersen M, Schioth HB, Gloriam DE. Trends in GPCR drug discovery: new agents, targets and indications. Nat Rev Drug Discov. 2017;16(12):829–42.29075003 10.1038/nrd.2017.178
8. Ferenbach DA Bonventre JV Mechanisms of maladaptive repair after AKI leading to accelerated kidney ageing and CKD Nat Rev Nephrol 2015 11 5 264 76 10.1038/nrneph.2015.3 25643664
Ferenbach DA, Bonventre JV. Mechanisms of maladaptive repair after AKI leading to accelerated kidney ageing and CKD. Nat Rev Nephrol. 2015;11(5):264–76.25643664 10.1038/nrneph.2015.3
9. Brezis M Rosen S Hypoxia of the renal medulla–its implications for disease N Engl J Med 1995 332 10 647 55 10.1056/NEJM199503093321006 7845430
Brezis M, Rosen S. Hypoxia of the renal medulla–its implications for disease. N Engl J Med. 1995;332(10):647–55.7845430 10.1056/NEJM199503093321006
10. Scholz H Boivin FJ Schmidt-Ott KM Bachmann S Eckardt KU Scholl UI Kidney physiology and susceptibility to acute kidney injury: implications for renoprotection Nat Rev Nephrol 2021 17 5 335 49 10.1038/s41581-021-00394-7 33547418
Scholz H, Boivin FJ, Schmidt-Ott KM, Bachmann S, Eckardt KU, Scholl UI, et al. Kidney physiology and susceptibility to acute kidney injury: implications for renoprotection. Nat Rev Nephrol. 2021;17(5):335–49.33547418 10.1038/s41581-021-00394-7
11. Kitching AR Hickey MJ Immune cell behaviour and dynamics in the kidney - insights from in vivo imaging Nat Rev Nephrol 2022 18 1 22 37 10.1038/s41581-021-00481-9 34556836
Kitching AR, Hickey MJ. Immune cell behaviour and dynamics in the kidney - insights from in vivo imaging. Nat Rev Nephrol. 2022;18(1):22–37.34556836 10.1038/s41581-021-00481-9
12. Sharma N Anders HJ Gaikwad AB Fiend and friend in the renin angiotensin system: an insight on acute kidney injury Biomed Pharmacother 2019 110 764 74 10.1016/j.biopha.2018.12.018 30554115
Sharma N, Anders HJ, Gaikwad AB. Fiend and friend in the renin angiotensin system: an insight on acute kidney injury. Biomed Pharmacother. 2019;110:764–74.30554115 10.1016/j.biopha.2018.12.018
13. Cruz-Lopez EO Ye D Wu C Lu HS Uijl E Mirabito Colafella KM Angiotensinogen suppression: a New Tool to treat Cardiovascular and Renal Disease Hypertension 2022 79 10 2115 26 10.1161/HYPERTENSIONAHA.122.18731 35904033
Cruz-Lopez EO, Ye D, Wu C, Lu HS, Uijl E, Mirabito Colafella KM, et al. Angiotensinogen suppression: a New Tool to treat Cardiovascular and Renal Disease. Hypertension. 2022;79(10):2115–26.35904033 10.1161/HYPERTENSIONAHA.122.18731
14. Karimi F Maleki M Nematbakhsh M View of the renin-angiotensin system in Acute kidney Injury Induced by Renal Ischemia-Reperfusion Injury J Renin Angiotensin Aldosterone Syst 2022 2022 9800838 10.1155/2022/9800838 36320442
Karimi F, Maleki M, Nematbakhsh M. View of the renin-angiotensin system in Acute kidney Injury Induced by Renal Ischemia-Reperfusion Injury. J Renin Angiotensin Aldosterone Syst. 2022;2022:9800838.36320442 10.1155/2022/9800838
15. Prieto MC Gonzalez AA Visniauskas B Navar LG The evolving complexity of the collecting duct renin-angiotensin system in hypertension Nat Rev Nephrol 2021 17 7 481 92 10.1038/s41581-021-00414-6 33824491
Prieto MC, Gonzalez AA, Visniauskas B, Navar LG. The evolving complexity of the collecting duct renin-angiotensin system in hypertension. Nat Rev Nephrol. 2021;17(7):481–92.33824491 10.1038/s41581-021-00414-6
16. Brar S Ye F James MT Hemmelgarn B Klarenbach S Pannu N Association of Angiotensin-Converting Enzyme Inhibitor or angiotensin receptor blocker Use with outcomes after Acute kidney Injury JAMA Intern Med 2018 178 12 1681 90 10.1001/jamainternmed.2018.4749 30422153
Brar S, Ye F, James MT, Hemmelgarn B, Klarenbach S, Pannu N, et al. Association of Angiotensin-Converting Enzyme Inhibitor or angiotensin receptor blocker Use with outcomes after Acute kidney Injury. JAMA Intern Med. 2018;178(12):1681–90.30422153 10.1001/jamainternmed.2018.4749
17. Chou YH Huang TM Pan SY Chang CH Lai CF Wu VC Renin-angiotensin system inhibitor is Associated with Lower Risk of ensuing chronic kidney disease after functional recovery from Acute kidney Injury Sci Rep 2017 7 46518 10.1038/srep46518 28406186
Chou YH, Huang TM, Pan SY, Chang CH, Lai CF, Wu VC, et al. Renin-angiotensin system inhibitor is Associated with Lower Risk of ensuing chronic kidney disease after functional recovery from Acute kidney Injury. Sci Rep. 2017;7:46518.28406186 10.1038/srep46518
18. Gayat E Hollinger A Cariou A Deye N Vieillard-Baron A Jaber S Impact of angiotensin-converting enzyme inhibitors or receptor blockers on post-ICU discharge outcome in patients with acute kidney injury Intensive Care Med 2018 44 5 598 605 10.1007/s00134-018-5160-6 29766216
Gayat E, Hollinger A, Cariou A, Deye N, Vieillard-Baron A, Jaber S, et al. Impact of angiotensin-converting enzyme inhibitors or receptor blockers on post-ICU discharge outcome in patients with acute kidney injury. Intensive Care Med. 2018;44(5):598–605.29766216 10.1007/s00134-018-5160-6
19. Berry C Touyz R Dominiczak AF Webb RC Johns DG Angiotensin receptors: signaling, vascular pathophysiology, and interactions with ceramide Am J Physiol Heart Circ Physiol 2001 281 6 H2337 65 10.1152/ajpheart.2001.281.6.H2337 11709400
Berry C, Touyz R, Dominiczak AF, Webb RC, Johns DG. Angiotensin receptors: signaling, vascular pathophysiology, and interactions with ceramide. Am J Physiol Heart Circ Physiol. 2001;281(6):H2337–65.11709400 10.1152/ajpheart.2001.281.6.H2337
20. de Gasparo M Catt KJ Inagami T Wright JW Unger T International union of pharmacology. XXIII. The angiotensin II receptors Pharmacol Rev 2000 52 3 415 72 10977869
de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev. 2000;52(3):415–72.10977869
21. Patel S Kulkarni K Hussain T Protecting glomerulus: role of angiotensin-II type 2 receptor Clin Sci (Lond) 2022 136 20 1467 70 10.1042/CS20220396 36287192
Patel S, Kulkarni K, Hussain T. Protecting glomerulus: role of angiotensin-II type 2 receptor. Clin Sci (Lond). 2022;136(20):1467–70.36287192 10.1042/CS20220396
22. Miura S Matsuo Y Kiya Y Karnik SS Saku K Molecular mechanisms of the antagonistic action between AT1 and AT2 receptors Biochem Biophys Res Commun 2010 391 1 85 90 10.1016/j.bbrc.2009.11.008 19896468
Miura S, Matsuo Y, Kiya Y, Karnik SS, Saku K. Molecular mechanisms of the antagonistic action between AT1 and AT2 receptors. Biochem Biophys Res Commun. 2010;391(1):85–90.19896468 10.1016/j.bbrc.2009.11.008
23. Sharma N Gaikwad AB Ameliorative effect of AT2R and ACE2 activation on ischemic renal injury associated cardiac and hepatic dysfunction Environ Toxicol Pharmacol 2020 80 103501 10.1016/j.etap.2020.103501 32979558
Sharma N, Gaikwad AB. Ameliorative effect of AT2R and ACE2 activation on ischemic renal injury associated cardiac and hepatic dysfunction. Environ Toxicol Pharmacol. 2020;80:103501.32979558 10.1016/j.etap.2020.103501
24. Fussi MF Hidalgo F Buono GM Marquez SB Pariani AP Molinas JL Angiotensin II type 2 receptor agonist, compound 21, prevents tubular epithelial cell damage caused by renal ischemia Biochem Pharmacol 2021 194 114804 10.1016/j.bcp.2021.114804 34678223
Fussi MF, Hidalgo F, Buono GM, Marquez SB, Pariani AP, Molinas JL, et al. Angiotensin II type 2 receptor agonist, compound 21, prevents tubular epithelial cell damage caused by renal ischemia. Biochem Pharmacol. 2021;194:114804.34678223 10.1016/j.bcp.2021.114804
25. Fatima N Patel S Hussain T Angiotensin AT2 receptor is anti-inflammatory and Reno-Protective in Lipopolysaccharide mice Model: role of IL-10 Front Pharmacol 2021 12 600163 10.3389/fphar.2021.600163 33935698
Fatima N, Patel S, Hussain T. Angiotensin AT2 receptor is anti-inflammatory and Reno-Protective in Lipopolysaccharide mice Model: role of IL-10. Front Pharmacol. 2021;12:600163.33935698 10.3389/fphar.2021.600163
26. Abdel-Hakeem EA Abdel Hafez SMN Kamel BA Abdel-Hamid HA Angiotensin 1–7 mitigates rhabdomyolysis induced renal injury in rats via modulation of TLR-4/NF-kB/iNOS and Nrf-2/heme–oxygenase-1 signaling pathways Life Sci 2022 303 120678 10.1016/j.lfs.2022.120678 35654118
Abdel-Hakeem EA, Abdel Hafez SMN, Kamel BA, Abdel-Hamid HA. Angiotensin 1–7 mitigates rhabdomyolysis induced renal injury in rats via modulation of TLR-4/NF-kB/iNOS and Nrf-2/heme–oxygenase-1 signaling pathways. Life Sci. 2022;303:120678.35654118 10.1016/j.lfs.2022.120678
27. da Silveira KD Pompermayer Bosco KS Diniz LR Carmona AK Cassali GD Bruna-Romero O ACE2-angiotensin-(1–7)-Mas axis in renal ischaemia/reperfusion injury in rats Clin Sci (Lond) 2010 119 9 385 94 10.1042/CS20090554 20528771
da Silveira KD, Pompermayer Bosco KS, Diniz LR, Carmona AK, Cassali GD, Bruna-Romero O, et al. ACE2-angiotensin-(1–7)-Mas axis in renal ischaemia/reperfusion injury in rats. Clin Sci (Lond). 2010;119(9):385–94.20528771 10.1042/CS20090554
28. Barroso LC Silveira KD Lima CX Borges V Bader M Rachid M Renoprotective effects of AVE0991, a nonpeptide mas receptor agonist, in experimental Acute Renal Injury Int J Hypertens 2012 2012 808726 10.1155/2012/808726 22319645
Barroso LC, Silveira KD, Lima CX, Borges V, Bader M, Rachid M, et al. Renoprotective effects of AVE0991, a nonpeptide mas receptor agonist, in experimental Acute Renal Injury. Int J Hypertens. 2012;2012:808726.22319645 10.1155/2012/808726
29. Kong Y Zhao X Qiu M Lin Y Feng P Li S Tubular mas receptor mediates lipid-induced kidney injury Cell Death Dis 2021 12 1 110 10.1038/s41419-020-03375-z 33479200
Kong Y, Zhao X, Qiu M, Lin Y, Feng P, Li S, et al. Tubular mas receptor mediates lipid-induced kidney injury. Cell Death Dis. 2021;12(1):110.33479200 10.1038/s41419-020-03375-z
30. Zimmerman DL Zimpelmann J Xiao F Gutsol A Touyz R Burns KD The effect of angiotensin-(1–7) in mouse unilateral ureteral obstruction Am J Pathol 2015 185 3 729 40 10.1016/j.ajpath.2014.11.013 25625676
Zimmerman DL, Zimpelmann J, Xiao F, Gutsol A, Touyz R, Burns KD. The effect of angiotensin-(1–7) in mouse unilateral ureteral obstruction. Am J Pathol. 2015;185(3):729–40.25625676 10.1016/j.ajpath.2014.11.013
31. Wang L Wu Y Jia Z Yu J Huang S Roles of EP receptors in the regulation of Fluid Balance and Blood pressure Front Endocrinol (Lausanne) 2022 13 875425 10.3389/fendo.2022.875425 35813612
Wang L, Wu Y, Jia Z, Yu J, Huang S. Roles of EP receptors in the regulation of Fluid Balance and Blood pressure. Front Endocrinol (Lausanne). 2022;13:875425.35813612 10.3389/fendo.2022.875425
32. Nasrallah R Hassouneh R Hebert RL PGE2, kidney disease, and Cardiovascular Risk: beyond hypertension and diabetes J Am Soc Nephrol 2016 27 3 666 76 10.1681/ASN.2015050528 26319242
Nasrallah R, Hassouneh R, Hebert RL. PGE2, kidney disease, and Cardiovascular Risk: beyond hypertension and diabetes. J Am Soc Nephrol. 2016;27(3):666–76.26319242 10.1681/ASN.2015050528
33. Breyer MD Breyer RM G protein-coupled prostanoid receptors and the kidney Annu Rev Physiol 2001 63 579 605 10.1146/annurev.physiol.63.1.579 11181968
Breyer MD, Breyer RM. G protein-coupled prostanoid receptors and the kidney. Annu Rev Physiol. 2001;63:579–605.11181968 10.1146/annurev.physiol.63.1.579
34. Pan Y Cao S Terker AS Tang J Sasaki K Wang Y Myeloid cyclooxygenase-2/prostaglandin E2/E-type prostanoid receptor 4 promotes transcription factor MafB-dependent inflammatory resolution in acute kidney injury Kidney Int 2022 101 1 79 91 10.1016/j.kint.2021.09.033 34774558
Pan Y, Cao S, Terker AS, Tang J, Sasaki K, Wang Y, et al. Myeloid cyclooxygenase-2/prostaglandin E2/E-type prostanoid receptor 4 promotes transcription factor MafB-dependent inflammatory resolution in acute kidney injury. Kidney Int. 2022;101(1):79–91.34774558 10.1016/j.kint.2021.09.033
35. Hong YA Yang KJ Jung SY Park KC Choi H Oh JM Paricalcitol pretreatment attenuates renal ischemia-reperfusion Injury via Prostaglandin E(2) receptor EP4 pathway Oxid Med Cell Longev 2017 2017 5031926 10.1155/2017/5031926 28465762
Hong YA, Yang KJ, Jung SY, Park KC, Choi H, Oh JM, et al. Paricalcitol pretreatment attenuates renal ischemia-reperfusion Injury via Prostaglandin E(2) receptor EP4 pathway. Oxid Med Cell Longev. 2017;2017:5031926.28465762 10.1155/2017/5031926
36. Hwang HS Yang KJ Park KC Choi HS Kim SH Hong SY Pretreatment with paricalcitol attenuates inflammation in ischemia-reperfusion injury via the up-regulation of cyclooxygenase-2 and prostaglandin E2 Nephrol Dial Transpl 2013 28 5 1156 66 10.1093/ndt/gfs540
Hwang HS, Yang KJ, Park KC, Choi HS, Kim SH, Hong SY, et al. Pretreatment with paricalcitol attenuates inflammation in ischemia-reperfusion injury via the up-regulation of cyclooxygenase-2 and prostaglandin E2. Nephrol Dial Transpl. 2013;28(5):1156–66.10.1093/ndt/gfs540
37. Guan X Liu Y Xin W Qin S Gong S Xiao T Activation of EP4 alleviates AKI-to-CKD transition through inducing CPT2-mediated lipophagy in renal macrophages Front Pharmacol 2022 13 1030800 10.3389/fphar.2022.1030800 36467025
Guan X, Liu Y, Xin W, Qin S, Gong S, Xiao T, et al. Activation of EP4 alleviates AKI-to-CKD transition through inducing CPT2-mediated lipophagy in renal macrophages. Front Pharmacol. 2022;13:1030800.36467025 10.3389/fphar.2022.1030800
38. Liu X, Yu T, Tan X, Jin D, Yang W, Zhang J et al. Renal interstitial cells promote nephron regeneration by secreting prostaglandin E2. Elife. 2023;12.
39. Ding C Han F Xiang H Wang Y Dou M Xia X Role of prostaglandin E2 receptor 4 in the modulation of apoptosis and mitophagy during ischemia/reperfusion injury in the kidney Mol Med Rep 2019 20 4 3337 46 31432142
Ding C, Han F, Xiang H, Wang Y, Dou M, Xia X, et al. Role of prostaglandin E2 receptor 4 in the modulation of apoptosis and mitophagy during ischemia/reperfusion injury in the kidney. Mol Med Rep. 2019;20(4):3337–46.31432142
40. Ranganathan PV Jayakumar C Mohamed R Dong Z Ramesh G Netrin-1 regulates the inflammatory response of neutrophils and macrophages, and suppresses ischemic acute kidney injury by inhibiting COX-2-mediated PGE2 production Kidney Int 2013 83 6 1087 98 10.1038/ki.2012.423 23447066
Ranganathan PV, Jayakumar C, Mohamed R, Dong Z, Ramesh G. Netrin-1 regulates the inflammatory response of neutrophils and macrophages, and suppresses ischemic acute kidney injury by inhibiting COX-2-mediated PGE2 production. Kidney Int. 2013;83(6):1087–98.23447066 10.1038/ki.2012.423
41. Menzies RI Tam FW Unwin RJ Bailey MA Purinergic signaling in kidney disease Kidney Int 2017 91 2 315 23 10.1016/j.kint.2016.08.029 27780585
Menzies RI, Tam FW, Unwin RJ, Bailey MA. Purinergic signaling in kidney disease. Kidney Int. 2017;91(2):315–23.27780585 10.1016/j.kint.2016.08.029
42. Dwyer KM Kishore BK Robson SC Conversion of extracellular ATP into adenosine: a master switch in renal health and disease Nat Rev Nephrol 2020 16 9 509 24 10.1038/s41581-020-0304-7 32641760
Dwyer KM, Kishore BK, Robson SC. Conversion of extracellular ATP into adenosine: a master switch in renal health and disease. Nat Rev Nephrol. 2020;16(9):509–24.32641760 10.1038/s41581-020-0304-7
43. Solini A Usuelli V Fiorina P The dark side of extracellular ATP in kidney diseases J Am Soc Nephrol 2015 26 5 1007 16 10.1681/ASN.2014070721 25452669
Solini A, Usuelli V, Fiorina P. The dark side of extracellular ATP in kidney diseases. J Am Soc Nephrol. 2015;26(5):1007–16.25452669 10.1681/ASN.2014070721
44. Zhang Y Yuan F Cao X Zhai Z GangHuang, Du X P2 × 7 receptor blockade protects against cisplatin-induced nephrotoxicity in mice by decreasing the activities of inflammasome components, oxidative stress and caspase-3 Toxicol Appl Pharmacol 2014 281 1 1 10 10.1016/j.taap.2014.09.016 25308879
Zhang Y, Yuan F, Cao X, Zhai Z, GangHuang, Du X, et al. P2X7 receptor blockade protects against cisplatin-induced nephrotoxicity in mice by decreasing the activities of inflammasome components, oxidative stress and caspase-3. Toxicol Appl Pharmacol. 2014;281(1):1–10.25308879 10.1016/j.taap.2014.09.016
45. Qian Y Qian C Xie K Fan Q Yan Y Lu R P2 × 7 receptor signaling promotes inflammation in renal parenchymal cells suffering from ischemia-reperfusion injury Cell Death Dis 2021 12 1 132 10.1038/s41419-020-03384-y 33504771
Qian Y, Qian C, Xie K, Fan Q, Yan Y, Lu R, et al. P2X7 receptor signaling promotes inflammation in renal parenchymal cells suffering from ischemia-reperfusion injury. Cell Death Dis. 2021;12(1):132.33504771 10.1038/s41419-020-03384-y
46. Arulkumaran N, Sixma ML, Pollen S, Ceravola E, Jentho E, Prendecki M et al. P2X(7) receptor antagonism ameliorates renal dysfunction in a rat model of sepsis. Physiol Rep. 2018;6(5).
47. Battistone MA Mendelsohn AC Spallanzani RG Allegretti AS Liberman RN Sesma J Proinflammatory P2Y14 receptor inhibition protects against ischemic acute kidney injury in mice J Clin Invest 2020 130 7 3734 49 10.1172/JCI134791 32287042
Battistone MA, Mendelsohn AC, Spallanzani RG, Allegretti AS, Liberman RN, Sesma J, et al. Proinflammatory P2Y14 receptor inhibition protects against ischemic acute kidney injury in mice. J Clin Invest. 2020;130(7):3734–49.32287042 10.1172/JCI134791
48. Wang M Jiang F Zhang L Zhang J Xie H Knockdown of P2Y4 ameliorates sepsis-induced acute kidney injury in mice via inhibiting the activation of the NF-kappaB/MMP8 axis Front Physiol 2022 13 953977 10.3389/fphys.2022.953977 36105291
Wang M, Jiang F, Zhang L, Zhang J, Xie H. Knockdown of P2Y4 ameliorates sepsis-induced acute kidney injury in mice via inhibiting the activation of the NF-kappaB/MMP8 axis. Front Physiol. 2022;13:953977.36105291 10.3389/fphys.2022.953977
49. Hansen PB Schnermann J Vasoconstrictor and vasodilator effects of adenosine in the kidney Am J Physiol Ren Physiol 2003 285 4 F590 9 10.1152/ajprenal.00051.2003
Hansen PB, Schnermann J. Vasoconstrictor and vasodilator effects of adenosine in the kidney. Am J Physiol Ren Physiol. 2003;285(4):F590–9.10.1152/ajprenal.00051.2003
50. Vincent IS Okusa MD Adenosine 2A receptors in acute kidney injury Acta Physiol (Oxf) 2015 214 3 303 10 10.1111/apha.12508 25877257
Vincent IS, Okusa MD. Adenosine 2A receptors in acute kidney injury. Acta Physiol (Oxf). 2015;214(3):303–10.25877257 10.1111/apha.12508
51. Rabadi MM Lee HT Adenosine receptors and renal ischaemia reperfusion injury Acta Physiol (Oxf) 2015 213 1 222 31 10.1111/apha.12402 25287331
Rabadi MM, Lee HT. Adenosine receptors and renal ischaemia reperfusion injury. Acta Physiol (Oxf). 2015;213(1):222–31.25287331 10.1111/apha.12402
52. Li L Okusa MD Macrophages, dendritic cells, and kidney ischemia-reperfusion injury Semin Nephrol 2010 30 3 268 77 10.1016/j.semnephrol.2010.03.005 20620671
Li L, Okusa MD. Macrophages, dendritic cells, and kidney ischemia-reperfusion injury. Semin Nephrol. 2010;30(3):268–77.20620671 10.1016/j.semnephrol.2010.03.005
53. Gessi S Varani K Merighi S Ongini E Borea PA A(2A) adenosine receptors in human peripheral blood cells Br J Pharmacol 2000 129 1 2 11 10.1038/sj.bjp.0703045 10694196
Gessi S, Varani K, Merighi S, Ongini E, Borea PA. A(2A) adenosine receptors in human peripheral blood cells. Br J Pharmacol. 2000;129(1):2–11.10694196 10.1038/sj.bjp.0703045
54. Lappas CM Day YJ Marshall MA Engelhard VH Linden J Adenosine A2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1d-dependent NKT cell activation J Exp Med 2006 203 12 2639 48 10.1084/jem.20061097 17088433
Lappas CM, Day YJ, Marshall MA, Engelhard VH, Linden J. Adenosine A2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1d-dependent NKT cell activation. J Exp Med. 2006;203(12):2639–48.17088433 10.1084/jem.20061097
55. Street JM Koritzinsky EH Bellomo TR Hu X Yuen PST Star RA The role of adenosine 1a receptor signaling on GFR early after the induction of sepsis Am J Physiol Ren Physiol 2018 314 5 F788 97 10.1152/ajprenal.00051.2017
Street JM, Koritzinsky EH, Bellomo TR, Hu X, Yuen PST, Star RA. The role of adenosine 1a receptor signaling on GFR early after the induction of sepsis. Am J Physiol Ren Physiol. 2018;314(5):F788–97.10.1152/ajprenal.00051.2017
56. Day YJ Huang L Ye H Linden J Okusa MD Renal ischemia-reperfusion injury and adenosine 2A receptor-mediated tissue protection: role of macrophages Am J Physiol Ren Physiol 2005 288 4 F722 31 10.1152/ajprenal.00378.2004
Day YJ, Huang L, Ye H, Linden J, Okusa MD. Renal ischemia-reperfusion injury and adenosine 2A receptor-mediated tissue protection: role of macrophages. Am J Physiol Ren Physiol. 2005;288(4):F722–31.10.1152/ajprenal.00378.2004
57. Day YJ Huang L McDuffie MJ Rosin DL Ye H Chen JF Renal protection from ischemia mediated by A2A adenosine receptors on bone marrow-derived cells J Clin Invest 2003 112 6 883 91 10.1172/JCI15483 12975473
Day YJ, Huang L, McDuffie MJ, Rosin DL, Ye H, Chen JF, et al. Renal protection from ischemia mediated by A2A adenosine receptors on bone marrow-derived cells. J Clin Invest. 2003;112(6):883–91.12975473 10.1172/JCI15483
58. Grenz A Bauerle JD Dalton JH Ridyard D Badulak A Tak E Equilibrative nucleoside transporter 1 (ENT1) regulates postischemic blood flow during acute kidney injury in mice J Clin Invest 2017 127 6 2438 10.1172/JCI94890 28569735
Grenz A, Bauerle JD, Dalton JH, Ridyard D, Badulak A, Tak E, et al. Equilibrative nucleoside transporter 1 (ENT1) regulates postischemic blood flow during acute kidney injury in mice. J Clin Invest. 2017;127(6):2438.28569735 10.1172/JCI94890
59. Kano K Aoki J Hla T Lysophospholipid mediators in Health and Disease Annu Rev Pathol 2022 17 459 83 10.1146/annurev-pathol-050420-025929 34813354
Kano K, Aoki J, Hla T. Lysophospholipid mediators in Health and Disease. Annu Rev Pathol. 2022;17:459–83.34813354 10.1146/annurev-pathol-050420-025929
60. Hemmings DG Brindley DN Signalling by lysophosphatidate and its health implications Essays Biochem 2020 64 3 547 63 10.1042/EBC20190088 32451553
Hemmings DG, Brindley DN. Signalling by lysophosphatidate and its health implications. Essays Biochem. 2020;64(3):547–63.32451553 10.1042/EBC20190088
61. Park F Miller DD Role of lysophosphatidic acid and its receptors in the kidney Physiol Genomics 2017 49 11 659 66 10.1152/physiolgenomics.00070.2017 28939644
Park F, Miller DD. Role of lysophosphatidic acid and its receptors in the kidney. Physiol Genomics. 2017;49(11):659–66.28939644 10.1152/physiolgenomics.00070.2017
62. Okusa MD Ye H Huang L Sigismund L Macdonald T Lynch KR Selective blockade of lysophosphatidic acid LPA3 receptors reduces murine renal ischemia-reperfusion injury Am J Physiol Ren Physiol 2003 285 3 F565 74 10.1152/ajprenal.00023.2003
Okusa MD, Ye H, Huang L, Sigismund L, Macdonald T, Lynch KR. Selective blockade of lysophosphatidic acid LPA3 receptors reduces murine renal ischemia-reperfusion injury. Am J Physiol Ren Physiol. 2003;285(3):F565–74.10.1152/ajprenal.00023.2003
63. de Vries B Matthijsen RA van Bijnen AA Wolfs TG Buurman WA Lysophosphatidic acid prevents renal ischemia-reperfusion injury by inhibition of apoptosis and complement activation Am J Pathol 2003 163 1 47 56 10.1016/S0002-9440(10)63629-2 12819010
de Vries B, Matthijsen RA, van Bijnen AA, Wolfs TG, Buurman WA. Lysophosphatidic acid prevents renal ischemia-reperfusion injury by inhibition of apoptosis and complement activation. Am J Pathol. 2003;163(1):47–56.12819010 10.1016/S0002-9440(10)63629-2
64. Gao J Zhang D Yang X Zhang Y Li P Su X Lysophosphatidic acid and lovastatin might protect kidney in renal I/R injury by downregulating MCP-1 in rat Ren Fail 2011 33 8 805 10 10.3109/0886022X.2011.601829 21815729
Gao J, Zhang D, Yang X, Zhang Y, Li P, Su X. Lysophosphatidic acid and lovastatin might protect kidney in renal I/R injury by downregulating MCP-1 in rat. Ren Fail. 2011;33(8):805–10.21815729 10.3109/0886022X.2011.601829
65. Geng H Lan R Liu Y Chen W Wu M Saikumar P Proximal tubule LPA1 and LPA2 receptors use divergent signaling pathways to additively increase profibrotic cytokine secretion Am J Physiol Ren Physiol 2021 320 3 F359 74 10.1152/ajprenal.00494.2020
Geng H, Lan R, Liu Y, Chen W, Wu M, Saikumar P, et al. Proximal tubule LPA1 and LPA2 receptors use divergent signaling pathways to additively increase profibrotic cytokine secretion. Am J Physiol Ren Physiol. 2021;320(3):F359–74.10.1152/ajprenal.00494.2020
66. Kimura T Sato K Kuwabara A Tomura H Ishiwara M Kobayashi I Sphingosine 1-phosphate may be a major component of plasma lipoproteins responsible for the cytoprotective actions in human umbilical vein endothelial cells J Biol Chem 2001 276 34 31780 5 10.1074/jbc.M104353200 11427538
Kimura T, Sato K, Kuwabara A, Tomura H, Ishiwara M, Kobayashi I, et al. Sphingosine 1-phosphate may be a major component of plasma lipoproteins responsible for the cytoprotective actions in human umbilical vein endothelial cells. J Biol Chem. 2001;276(34):31780–5.11427538 10.1074/jbc.M104353200
67. Hla T Lee MJ Ancellin N Paik JH Kluk MJ Lysophospholipids–receptor revelations Science 2001 294 5548 1875 8 10.1126/science.1065323 11729304
Hla T, Lee MJ, Ancellin N, Paik JH, Kluk MJ. Lysophospholipids–receptor revelations. Science. 2001;294(5548):1875–8.11729304 10.1126/science.1065323
68. Jo SK Bajwa A Awad AS Lynch KR Okusa MD Sphingosine-1-phosphate receptors: biology and therapeutic potential in kidney disease Kidney Int 2008 73 11 1220 30 10.1038/ki.2008.34 18322542
Jo SK, Bajwa A, Awad AS, Lynch KR, Okusa MD. Sphingosine-1-phosphate receptors: biology and therapeutic potential in kidney disease. Kidney Int. 2008;73(11):1220–30.18322542 10.1038/ki.2008.34
69. Bajwa A Jo SK Ye H Huang L Dondeti KR Rosin DL Activation of sphingosine-1-phosphate 1 receptor in the proximal tubule protects against ischemia-reperfusion injury J Am Soc Nephrol 2010 21 6 955 65 10.1681/ASN.2009060662 20338995
Bajwa A, Jo SK, Ye H, Huang L, Dondeti KR, Rosin DL, et al. Activation of sphingosine-1-phosphate 1 receptor in the proximal tubule protects against ischemia-reperfusion injury. J Am Soc Nephrol. 2010;21(6):955–65.20338995 10.1681/ASN.2009060662
70. Kirby RJ Jin Y Fu J Cubillos J Swertfeger D Arend LJ Dynamic regulation of sphingosine-1-phosphate homeostasis during development of mouse metanephric kidney Am J Physiol Ren Physiol 2009 296 3 F634 41 10.1152/ajprenal.90232.2008
Kirby RJ, Jin Y, Fu J, Cubillos J, Swertfeger D, Arend LJ. Dynamic regulation of sphingosine-1-phosphate homeostasis during development of mouse metanephric kidney. Am J Physiol Ren Physiol. 2009;296(3):F634–41.10.1152/ajprenal.90232.2008
71. Park SW Kim M Kim M D’Agati VD Lee HT Sphingosine kinase 1 protects against renal ischemia-reperfusion injury in mice by sphingosine-1-phosphate1 receptor activation Kidney Int 2011 80 12 1315 27 10.1038/ki.2011.281 21849969
Park SW, Kim M, Kim M, D’Agati VD, Lee HT. Sphingosine kinase 1 protects against renal ischemia-reperfusion injury in mice by sphingosine-1-phosphate1 receptor activation. Kidney Int. 2011;80(12):1315–27.21849969 10.1038/ki.2011.281
72. Park SW Kim M Brown KM D’Agati VD Lee HT Inhibition of sphingosine 1-phosphate receptor 2 protects against renal ischemia-reperfusion injury J Am Soc Nephrol 2012 23 2 266 80 10.1681/ASN.2011050503 22095950
Park SW, Kim M, Brown KM, D’Agati VD, Lee HT. Inhibition of sphingosine 1-phosphate receptor 2 protects against renal ischemia-reperfusion injury. J Am Soc Nephrol. 2012;23(2):266–80.22095950 10.1681/ASN.2011050503
73. Bajwa A Huang L Ye H Dondeti K Song S Rosin DL Dendritic cell sphingosine 1-phosphate receptor-3 regulates Th1-Th2 polarity in kidney ischemia-reperfusion injury J Immunol 2012 189 5 2584 96 10.4049/jimmunol.1200999 22855711
Bajwa A, Huang L, Ye H, Dondeti K, Song S, Rosin DL, et al. Dendritic cell sphingosine 1-phosphate receptor-3 regulates Th1-Th2 polarity in kidney ischemia-reperfusion injury. J Immunol. 2012;189(5):2584–96.22855711 10.4049/jimmunol.1200999
74. Bajwa A Huang L Kurmaeva E Gigliotti JC Ye H Miller J Sphingosine 1-Phosphate receptor 3-Deficient dendritic cells modulate splenic responses to Ischemia-Reperfusion Injury J Am Soc Nephrol 2016 27 4 1076 90 10.1681/ASN.2015010095 26286732
Bajwa A, Huang L, Kurmaeva E, Gigliotti JC, Ye H, Miller J, et al. Sphingosine 1-Phosphate receptor 3-Deficient dendritic cells modulate splenic responses to Ischemia-Reperfusion Injury. J Am Soc Nephrol. 2016;27(4):1076–90.26286732 10.1681/ASN.2015010095
75. Bajwa A Rosin DL Chroscicki P Lee S Dondeti K Ye H Sphingosine 1-phosphate receptor-1 enhances mitochondrial function and reduces cisplatin-induced tubule injury J Am Soc Nephrol 2015 26 4 908 25 10.1681/ASN.2013121351 25145931
Bajwa A, Rosin DL, Chroscicki P, Lee S, Dondeti K, Ye H, et al. Sphingosine 1-phosphate receptor-1 enhances mitochondrial function and reduces cisplatin-induced tubule injury. J Am Soc Nephrol. 2015;26(4):908–25.25145931 10.1681/ASN.2013121351
76. Rousselle TV Kuscu C Kuscu C Schlegel K Huang L Namwanje M FTY720 regulates Mitochondria Biogenesis in dendritic cells to prevent kidney ischemic reperfusion Injury Front Immunol 2020 11 1278 10.3389/fimmu.2020.01278 32670281
Rousselle TV, Kuscu C, Kuscu C, Schlegel K, Huang L, Namwanje M, et al. FTY720 regulates Mitochondria Biogenesis in dendritic cells to prevent kidney ischemic reperfusion Injury. Front Immunol. 2020;11:1278.32670281 10.3389/fimmu.2020.01278
77. Salvadori M Budde K Charpentier B Klempnauer J Nashan B Pallardo LM FTY720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year, randomized controlled trial in Europe and Australasia Am J Transpl 2006 6 12 2912 21 10.1111/j.1600-6143.2006.01552.x
Salvadori M, Budde K, Charpentier B, Klempnauer J, Nashan B, Pallardo LM, et al. FTY720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year, randomized controlled trial in Europe and Australasia. Am J Transpl. 2006;6(12):2912–21.10.1111/j.1600-6143.2006.01552.x
78. Hoitsma AJ Woodle ES Abramowicz D Proot P Vanrenterghem Y Group FTYPITS FTY720 combined with tacrolimus in de novo renal transplantation: 1-year, multicenter, open-label randomized study Nephrol Dial Transpl 2011 26 11 3802 5 10.1093/ndt/gfr503
Hoitsma AJ, Woodle ES, Abramowicz D, Proot P, Vanrenterghem Y, Group FTYPITS. FTY720 combined with tacrolimus in de novo renal transplantation: 1-year, multicenter, open-label randomized study. Nephrol Dial Transpl. 2011;26(11):3802–5.10.1093/ndt/gfr503
79. Herman-Edelstein M Weinstein T Levi M Bile acid receptors and the kidney Curr Opin Nephrol Hypertens 2018 27 1 56 62 10.1097/MNH.0000000000000374 29045336
Herman-Edelstein M, Weinstein T, Levi M. Bile acid receptors and the kidney. Curr Opin Nephrol Hypertens. 2018;27(1):56–62.29045336 10.1097/MNH.0000000000000374
80. Zhao CL Amin A Hui Y Yang D Cao W TGR5 expression in normal kidney and renal neoplasms Diagn Pathol 2018 13 1 22 10.1186/s13000-018-0700-5 29606134
Zhao CL, Amin A, Hui Y, Yang D, Cao W. TGR5 expression in normal kidney and renal neoplasms. Diagn Pathol. 2018;13(1):22.29606134 10.1186/s13000-018-0700-5
81. Zhang L, Fu X, Gui T, Wang T, Wang Z, Kullak-Ublick GA et al. Effects of Farnesiferol B on Ischemia-Reperfusion-Induced renal damage, inflammation, and NF-kappaB signaling. Int J Mol Sci. 2019;20(24).
82. Li S Qiu M Kong Y Zhao X Choi HJ Reich M Bile acid G protein-coupled membrane receptor TGR5 modulates aquaporin 2-Mediated water homeostasis J Am Soc Nephrol 2018 29 11 2658 70 10.1681/ASN.2018030271 30305310
Li S, Qiu M, Kong Y, Zhao X, Choi HJ, Reich M, et al. Bile acid G protein-coupled membrane receptor TGR5 modulates aquaporin 2-Mediated water homeostasis. J Am Soc Nephrol. 2018;29(11):2658–70.30305310 10.1681/ASN.2018030271
83. Han M Li S Xie H Liu Q Wang A Hu S Activation of TGR5 restores AQP2 expression via the HIF pathway in renal ischemia-reperfusion injury Am J Physiol Ren Physiol 2021 320 3 F308 21 10.1152/ajprenal.00577.2020
Han M, Li S, Xie H, Liu Q, Wang A, Hu S, et al. Activation of TGR5 restores AQP2 expression via the HIF pathway in renal ischemia-reperfusion injury. Am J Physiol Ren Physiol. 2021;320(3):F308–21.10.1152/ajprenal.00577.2020
84. Huang Z Guo F Xia Z Liang Y Lei S Tan Z Activation of GPR120 by TUG891 ameliorated cisplatin-induced acute kidney injury via repressing ER stress and apoptosis Biomed Pharmacother 2020 126 110056 10.1016/j.biopha.2020.110056 32145589
Huang Z, Guo F, Xia Z, Liang Y, Lei S, Tan Z, et al. Activation of GPR120 by TUG891 ameliorated cisplatin-induced acute kidney injury via repressing ER stress and apoptosis. Biomed Pharmacother. 2020;126:110056.32145589 10.1016/j.biopha.2020.110056
85. Yang L Wang B Guo F Huang R Liang Y Li L FFAR4 improves the senescence of tubular epithelial cells by AMPK/SirT3 signaling in acute kidney injury Signal Transduct Target Ther 2022 7 1 384 10.1038/s41392-022-01254-x 36450712
Yang L, Wang B, Guo F, Huang R, Liang Y, Li L, et al. FFAR4 improves the senescence of tubular epithelial cells by AMPK/SirT3 signaling in acute kidney injury. Signal Transduct Target Ther. 2022;7(1):384.36450712 10.1038/s41392-022-01254-x
86. Wang L Ren X Tian XF Cheng XL Zhao YY Li QY Protective effects of GPR120 agonist-programmed macrophages on renal interstitial fibrosis in unilateral ureteral obstruction (UUO) rats Biomed Pharmacother 2019 117 109172 10.1016/j.biopha.2019.109172 31261028
Wang L, Ren X, Tian XF, Cheng XL, Zhao YY, Li QY, et al. Protective effects of GPR120 agonist-programmed macrophages on renal interstitial fibrosis in unilateral ureteral obstruction (UUO) rats. Biomed Pharmacother. 2019;117:109172.31261028 10.1016/j.biopha.2019.109172
87. Ma SK Joo SY Choi HI Bae EH Nam KI Lee J Activation of G-protein-coupled receptor 40 attenuates the cisplatin-induced apoptosis of human renal proximal tubule epithelial cells Int J Mol Med 2014 34 4 1117 23 10.3892/ijmm.2014.1874 25092426
Ma SK, Joo SY, Choi HI, Bae EH, Nam KI, Lee J, et al. Activation of G-protein-coupled receptor 40 attenuates the cisplatin-induced apoptosis of human renal proximal tubule epithelial cells. Int J Mol Med. 2014;34(4):1117–23.25092426 10.3892/ijmm.2014.1874
88. Gagnon L Leduc M Thibodeau JF Zhang MZ Grouix B Sarra-Bournet F A newly discovered antifibrotic pathway regulated by two fatty acid receptors: GPR40 and GPR84 Am J Pathol 2018 188 5 1132 48 10.1016/j.ajpath.2018.01.009 29454750
Gagnon L, Leduc M, Thibodeau JF, Zhang MZ, Grouix B, Sarra-Bournet F, et al. A newly discovered antifibrotic pathway regulated by two fatty acid receptors: GPR40 and GPR84. Am J Pathol. 2018;188(5):1132–48.29454750 10.1016/j.ajpath.2018.01.009
89. Thibodeau JF Simard JC Holterman CE Blais A Cloutier MP Medeiros T PBI-4050 via GPR40 activation improves adenine-induced kidney injury in mice Clin Sci (Lond) 2019 133 14 1587 602 10.1042/CS20190479 31308217
Thibodeau JF, Simard JC, Holterman CE, Blais A, Cloutier MP, Medeiros T, et al. PBI-4050 via GPR40 activation improves adenine-induced kidney injury in mice. Clin Sci (Lond). 2019;133(14):1587–602.31308217 10.1042/CS20190479
90. Barutta F Bruno G Mastrocola R Bellini S Gruden G The role of cannabinoid signaling in acute and chronic kidney diseases Kidney Int 2018 94 2 252 8 10.1016/j.kint.2018.01.024 29706358
Barutta F, Bruno G, Mastrocola R, Bellini S, Gruden G. The role of cannabinoid signaling in acute and chronic kidney diseases. Kidney Int. 2018;94(2):252–8.29706358 10.1016/j.kint.2018.01.024
91. Mukhopadhyay P Pan H Rajesh M Batkai S Patel V Harvey-White J CB1 cannabinoid receptors promote oxidative/nitrosative stress, inflammation and cell death in a murine nephropathy model Br J Pharmacol 2010 160 3 657 68 10.1111/j.1476-5381.2010.00769.x 20590569
Mukhopadhyay P, Pan H, Rajesh M, Batkai S, Patel V, Harvey-White J, et al. CB1 cannabinoid receptors promote oxidative/nitrosative stress, inflammation and cell death in a murine nephropathy model. Br J Pharmacol. 2010;160(3):657–68.20590569 10.1111/j.1476-5381.2010.00769.x
92. Mukhopadhyay P Rajesh M Pan H Patel V Mukhopadhyay B Batkai S Cannabinoid-2 receptor limits inflammation, oxidative/nitrosative stress, and cell death in nephropathy Free Radic Biol Med 2010 48 3 457 67 10.1016/j.freeradbiomed.2009.11.022 19969072
Mukhopadhyay P, Rajesh M, Pan H, Patel V, Mukhopadhyay B, Batkai S, et al. Cannabinoid-2 receptor limits inflammation, oxidative/nitrosative stress, and cell death in nephropathy. Free Radic Biol Med. 2010;48(3):457–67.19969072 10.1016/j.freeradbiomed.2009.11.022
93. Li XH Liu YQ Gong DY Hai KR Ke BW Zuo YX The critical role of cannabinoid receptor 2 in URB602-Induced Protective effects against Renal Ischemia-Reperfusion Injury in the rat Shock 2020 54 4 520 30 10.1097/SHK.0000000000001517 32004183
Li XH, Liu YQ, Gong DY, Hai KR, Ke BW, Zuo YX. The critical role of cannabinoid receptor 2 in URB602-Induced Protective effects against Renal Ischemia-Reperfusion Injury in the rat. Shock. 2020;54(4):520–30.32004183 10.1097/SHK.0000000000001517
94. Norregaard R Kwon TH Frokiaer J Physiology and pathophysiology of cyclooxygenase-2 and prostaglandin E2 in the kidney Kidney Res Clin Pract 2015 34 4 194 200 10.1016/j.krcp.2015.10.004 26779421
Norregaard R, Kwon TH, Frokiaer J. Physiology and pathophysiology of cyclooxygenase-2 and prostaglandin E2 in the kidney. Kidney Res Clin Pract. 2015;34(4):194–200.26779421 10.1016/j.krcp.2015.10.004
95. Begg M Pacher P Batkai S Osei-Hyiaman D Offertaler L Mo FM Evidence for novel cannabinoid receptors Pharmacol Ther 2005 106 2 133 45 10.1016/j.pharmthera.2004.11.005 15866316
Begg M, Pacher P, Batkai S, Osei-Hyiaman D, Offertaler L, Mo FM, et al. Evidence for novel cannabinoid receptors. Pharmacol Ther. 2005;106(2):133–45.15866316 10.1016/j.pharmthera.2004.11.005
96. Chen R, Xu H, Guo Z, Zhang P, Chen J, Chen Z. CID16020046, a GPR55 antagonist, attenuates sepsis–induced acute kidney injury. Mol Med Rep. 2022;25(5).
97. Argyriou A, Wadsworth MH 2nd, Lendvai A, Christensen SM, Hensvold AH, Gerstner C, et al. Single cell sequencing identifies clonally expanded synovial CD4(+) T(PH) cells expressing GPR56 in rheumatoid arthritis. Nat Commun. 2022;13(1):4046.
98. Ng KF, Chen TC, Stacey M, Lin HH. Role of ADGRG1/GPR56 in Tumor Progression. Cells. 2021;10(12).
99. Zaidman NA Tomilin VN Hassanzadeh Khayyat N Damarla M Tidmore J Capen DE Adhesion-GPCR Gpr116 (ADGRF5) expression inhibits renal acid secretion Proc Natl Acad Sci U S A 2020 117 42 26470 81 10.1073/pnas.2007620117 33004624
Zaidman NA, Tomilin VN, Hassanzadeh Khayyat N, Damarla M, Tidmore J, Capen DE, et al. Adhesion-GPCR Gpr116 (ADGRF5) expression inhibits renal acid secretion. Proc Natl Acad Sci U S A. 2020;117(42):26470–81.33004624 10.1073/pnas.2007620117
100. Lu S Liu S Wietelmann A Kojonazarov B Atzberger A Tang C Developmental vascular remodeling defects and postnatal kidney failure in mice lacking Gpr116 (Adgrf5) and Eltd1 (Adgrl4) PLoS ONE 2017 12 8 e0183166 10.1371/journal.pone.0183166 28806758
Lu S, Liu S, Wietelmann A, Kojonazarov B, Atzberger A, Tang C, et al. Developmental vascular remodeling defects and postnatal kidney failure in mice lacking Gpr116 (Adgrf5) and Eltd1 (Adgrl4). PLoS ONE. 2017;12(8):e0183166.28806758 10.1371/journal.pone.0183166
101. Fang W Wang Z Li Q Wang X Zhang Y Sun Y Gpr97 exacerbates AKI by Mediating Sema3A Signaling J Am Soc Nephrol 2018 29 5 1475 89 10.1681/ASN.2017080932 29531097
Fang W, Wang Z, Li Q, Wang X, Zhang Y, Sun Y, et al. Gpr97 exacerbates AKI by Mediating Sema3A Signaling. J Am Soc Nephrol. 2018;29(5):1475–89.29531097 10.1681/ASN.2017080932
102. Anders HJ Muruve DA The inflammasomes in kidney disease J Am Soc Nephrol 2011 22 6 1007 18 10.1681/ASN.2010080798 21566058
Anders HJ, Muruve DA. The inflammasomes in kidney disease. J Am Soc Nephrol. 2011;22(6):1007–18.21566058 10.1681/ASN.2010080798
103. Chung AC Lan HY Chemokines in renal injury J Am Soc Nephrol 2011 22 5 802 9 10.1681/ASN.2010050510 21474561
Chung AC, Lan HY. Chemokines in renal injury. J Am Soc Nephrol. 2011;22(5):802–9.21474561 10.1681/ASN.2010050510
104. Zhuang Q Cheng K Ming Y CX3CL1/CX3CR1 Axis, as the therapeutic potential in renal diseases: friend or foe? Curr Gene Ther 2017 17 6 442 52 10.2174/1566523218666180214092536 29446734
Zhuang Q, Cheng K, Ming Y. CX3CL1/CX3CR1 Axis, as the therapeutic potential in renal diseases: friend or foe? Curr Gene Ther. 2017;17(6):442–52.29446734 10.2174/1566523218666180214092536
105. Fu Y Xiang Y Li H Chen A Dong Z Inflammation in kidney repair: mechanism and therapeutic potential Pharmacol Ther 2022 237 108240 10.1016/j.pharmthera.2022.108240 35803367
Fu Y, Xiang Y, Li H, Chen A, Dong Z. Inflammation in kidney repair: mechanism and therapeutic potential. Pharmacol Ther. 2022;237:108240.35803367 10.1016/j.pharmthera.2022.108240
106. Mathern DR Heeger PS Molecules great and small: the complement system Clin J Am Soc Nephrol 2015 10 9 1636 50 10.2215/CJN.06230614 25568220
Mathern DR, Heeger PS. Molecules great and small: the complement system. Clin J Am Soc Nephrol. 2015;10(9):1636–50.25568220 10.2215/CJN.06230614
107. Peng Q Li K Smyth LA Xing G Wang N Meader L C3a and C5a promote renal ischemia-reperfusion injury J Am Soc Nephrol 2012 23 9 1474 85 10.1681/ASN.2011111072 22797180
Peng Q, Li K, Smyth LA, Xing G, Wang N, Meader L, et al. C3a and C5a promote renal ischemia-reperfusion injury. J Am Soc Nephrol. 2012;23(9):1474–85.22797180 10.1681/ASN.2011111072
108. Salvadori M Rosso G Bertoni E Complement involvement in kidney diseases: from physiopathology to therapeutical targeting World J Nephrol 2015 4 2 169 84 10.5527/wjn.v4.i2.169 25949931
Salvadori M, Rosso G, Bertoni E. Complement involvement in kidney diseases: from physiopathology to therapeutical targeting. World J Nephrol. 2015;4(2):169–84.25949931 10.5527/wjn.v4.i2.169
109. Brilland B Garnier AS Chevailler A Jeannin P Subra JF Augusto JF Complement alternative pathway in ANCA-associated vasculitis: two decades from bench to bedside Autoimmun Rev 2020 19 1 102424 10.1016/j.autrev.2019.102424 31734405
Brilland B, Garnier AS, Chevailler A, Jeannin P, Subra JF, Augusto JF. Complement alternative pathway in ANCA-associated vasculitis: two decades from bench to bedside. Autoimmun Rev. 2020;19(1):102424.31734405 10.1016/j.autrev.2019.102424
110. Gao S Cui Z Zhao MH The complement C3a and C3a receptor pathway in kidney diseases Front Immunol 2020 11 1875 10.3389/fimmu.2020.01875 32973774
Gao S, Cui Z, Zhao MH. The complement C3a and C3a receptor pathway in kidney diseases. Front Immunol. 2020;11:1875.32973774 10.3389/fimmu.2020.01875
111. Li K Wu KY Wu W Wang N Zhang T Choudhry N C5aR1 promotes acute pyelonephritis induced by uropathogenic E. Coli JCI Insight 2017 2 24 10.1172/jci.insight.97626
Li K, Wu KY, Wu W, Wang N, Zhang T, Choudhry N, et al. C5aR1 promotes acute pyelonephritis induced by uropathogenic E. Coli. JCI Insight. 2017;2:24.10.1172/jci.insight.97626
112. Song Y Wu KY Wu W Duan ZY Gao YF Zhang LD Epithelial C5aR1 signaling enhances uropathogenic Escherichia coli adhesion to human renal tubular epithelial cells Front Immunol 2018 9 949 10.3389/fimmu.2018.00949 29765378
Song Y, Wu KY, Wu W, Duan ZY, Gao YF, Zhang LD, et al. Epithelial C5aR1 signaling enhances uropathogenic Escherichia coli adhesion to human renal tubular epithelial cells. Front Immunol. 2018;9:949.29765378 10.3389/fimmu.2018.00949
113. Wu KY Zhang T Zhao GX Ma N Zhao SJ Wang N The C3a/C3aR axis mediates anti-inflammatory activity and protects against uropathogenic E coli-induced kidney injury in mice Kidney Int 2019 96 3 612 27 10.1016/j.kint.2019.03.005 31133456
Wu KY, Zhang T, Zhao GX, Ma N, Zhao SJ, Wang N, et al. The C3a/C3aR axis mediates anti-inflammatory activity and protects against uropathogenic E coli-induced kidney injury in mice. Kidney Int. 2019;96(3):612–27.31133456 10.1016/j.kint.2019.03.005
114. Bidulka P Fu EL Leyrat C Kalogirou F McAllister KSL Kingdon EJ Stopping renin-angiotensin system blockers after acute kidney injury and risk of adverse outcomes: parallel population-based cohort studies in English and Swedish routine care BMC Med 2020 18 1 195 10.1186/s12916-020-01659-x 32723383
Bidulka P, Fu EL, Leyrat C, Kalogirou F, McAllister KSL, Kingdon EJ, et al. Stopping renin-angiotensin system blockers after acute kidney injury and risk of adverse outcomes: parallel population-based cohort studies in English and Swedish routine care. BMC Med. 2020;18(1):195.32723383 10.1186/s12916-020-01659-x
115. Wu VC Lin YF Teng NC Yang SY Chou NK Tsao CH Angiotensin II receptor blocker Associated with Less Outcome risk in patients with acute kidney disease Front Pharmacol 2022 13 714658 10.3389/fphar.2022.714658 35517809
Wu VC, Lin YF, Teng NC, Yang SY, Chou NK, Tsao CH, et al. Angiotensin II receptor blocker Associated with Less Outcome risk in patients with acute kidney disease. Front Pharmacol. 2022;13:714658.35517809 10.3389/fphar.2022.714658
116. Kellum JA Lameire N Group KAGW Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (part 1) Crit Care 2013 17 1 204 10.1186/cc11454 23394211
Kellum JA, Lameire N, Group KAGW. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (part 1). Crit Care. 2013;17(1):204.23394211 10.1186/cc11454
117. Wagener G Goldklang MP Gerber A Elisman K Eiseman KA Fonseca LD A randomized, placebo-controlled, double-blinded pilot study of angiotensin 1–7 (TXA-127) for the treatment of severe COVID-19 Crit Care 2022 26 1 229 10.1186/s13054-022-04096-9 35902867
Wagener G, Goldklang MP, Gerber A, Elisman K, Eiseman KA, Fonseca LD, et al. A randomized, placebo-controlled, double-blinded pilot study of angiotensin 1–7 (TXA-127) for the treatment of severe COVID-19. Crit Care. 2022;26(1):229.35902867 10.1186/s13054-022-04096-9
118. Bharathan VK Chandran B Gopalakrishnan U Varghese CT Menon RN Balakrishnan D Perioperative prostaglandin e1 infusion in living donor liver transplantation: a double-blind, placebo-controlled randomized trial Liver Transpl 2016 22 8 1067 74 10.1002/lt.24479 27152759
Bharathan VK, Chandran B, Gopalakrishnan U, Varghese CT, Menon RN, Balakrishnan D, et al. Perioperative prostaglandin e1 infusion in living donor liver transplantation: a double-blind, placebo-controlled randomized trial. Liver Transpl. 2016;22(8):1067–74.27152759 10.1002/lt.24479
119. De Filippo O D’Ascenzo F Raposeiras-Roubin S Abu-Assi E Peyracchia M Bocchino PP P2Y12 inhibitors in acute coronary syndrome patients with renal dysfunction: an analysis from the RENAMI and BleeMACS projects Eur Heart J Cardiovasc Pharmacother 2020 6 1 31 42 10.1093/ehjcvp/pvz048 31511896
De Filippo O, D’Ascenzo F, Raposeiras-Roubin S, Abu-Assi E, Peyracchia M, Bocchino PP, et al. P2Y12 inhibitors in acute coronary syndrome patients with renal dysfunction: an analysis from the RENAMI and BleeMACS projects. Eur Heart J Cardiovasc Pharmacother. 2020;6(1):31–42.31511896 10.1093/ehjcvp/pvz048
120. Menne J Is ravulizumab the new treatment of choice for atypical hemolytic uremic syndrome (aHUS)? Kidney Int 2020 97 6 1106 8 10.1016/j.kint.2020.03.011 32444092
Menne J. Is ravulizumab the new treatment of choice for atypical hemolytic uremic syndrome (aHUS)? Kidney Int. 2020;97(6):1106–8.32444092 10.1016/j.kint.2020.03.011
121. Memon AA Ahmed H Li Y Wongboonsin J Hundert J Benoit S A Randomized Control Trial of Ravulizumab for treatment of patients with COVID-19 infection and kidney Injury Kidney Int Rep 2022 7 12 2714 7 10.1016/j.ekir.2022.09.003 36120390
Memon AA, Ahmed H, Li Y, Wongboonsin J, Hundert J, Benoit S, et al. A Randomized Control Trial of Ravulizumab for treatment of patients with COVID-19 infection and kidney Injury. Kidney Int Rep. 2022;7(12):2714–7.36120390 10.1016/j.ekir.2022.09.003
